

Hypertension in adults: diagnosis and management

C. Evidence review for initiating treatment

NICE guideline

Intervention evidence review

March 2019

Draft for consultation

*This evidence review was developed by
the National Guideline Centre*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© National Institute for Health and Care Excellence, 2019

Contents

1	Initiating treatment	6
1.1	Review question: At what blood pressure and/or cardiovascular disease risk threshold should antihypertensive drug treatment be initiated for adults with hypertension?.....	6
1.2	Introduction	6
1.3	PICO table.....	6
1.4	Methods and process	7
1.5	Clinical evidence	7
1.5.1	Included studies	7
1.5.2	Summary of clinical studies included in the evidence review.....	8
1.5.3	Excluded studies.....	11
1.5.4	Quality assessment of clinical studies included in the evidence review	13
1.6	Economic evidence	18
1.6.1	Included studies	18
1.6.2	Excluded studies.....	18
1.6.3	Health economic modelling	19
1.6.4	Resource costs	23
1.7	Evidence statements	24
1.7.1	Clinical evidence statements.....	24
1.7.2	Health economic evidence statements.....	25
1.8	Recommendations	25
1.8.1	Research recommendations	26
1.9	Rationale and impact.....	Error! Bookmark not defined.
1.9.1	Why the committee made the recommendations.....	Error! Bookmark not defined.
1.9.2	Impact of the recommendations on practice	Error! Bookmark not defined.
1.10	The committee's discussion of the evidence.....	26
1.10.1	Interpreting the evidence.....	26
1.10.2	Cost effectiveness and resource use	29
1.10.3	Other factors the committee took into account	32
	Appendices	47
	Appendix A: Review protocols	47
	Appendix B: Literature search strategies	51
	B.1 Clinical search literature search strategy	51
	B.2 Health Economics literature search strategy.....	56
	Appendix C: Clinical evidence selection.....	60
	Appendix D: Clinical evidence tables	61
	Appendix E: Forest plots.....	72
	1.10.4 All-cause mortality at 4 years	72

1.10.5 Stroke at 4 years.....	72
1.10.6 Coronary heart disease at 4 years	73
1.10.7 Heart failure at 4 years.....	73
1.10.8 Stroke	74
Appendix F: GRADE tables	77
Appendix G: Health economic evidence selection	84
Appendix H: Health economic evidence tables	85
Appendix I: Excluded studies.....	85
I.1 Excluded clinical studies.....	85
I.2 Excluded health economic studies.....	89
Appendix J: Research recommendations	90

1 1 Initiating treatment

1.1 2 Review question: At what blood pressure and/or 3 cardiovascular disease risk threshold should 4 antihypertensive drug treatment be initiated for adults with 5 hypertension?

1.2 6 Introduction

7 Blood pressure varies across the population, and there is no natural cut-off point above
8 which 'hypertension' definitively exists and below which it does not. The threshold at which
9 treatment should be initiated is therefore based on a risk or benefit calculation.

10 The current UK recommendations for initiating antihypertensive treatment are based on a
11 combination of blood pressure levels and cardiovascular disease risk thresholds. Specifically,
12 in individuals with stage 1 hypertension (clinic blood pressure 140/90 to 159/99 mmHg)
13 antihypertensive treatment is only recommended if an individual's 10-year risk for
14 cardiovascular events is greater than 20%. This 2-step process for deciding when to initiate
15 treatment has the potential to result in confusion and contrasts to the recently published lipid
16 guideline in which treatment initiation is based on the cardiovascular disease risk threshold.
17 In this chapter, the evidence for initiating treatment based on blood pressure (BP) or
18 cardiovascular disease (CVD) risk thresholds is evaluated.

1.3 19 PICO table

20 For full details, see the review protocol in appendix A.

21 **Table 1: PICO characteristics of review question**

Population	At what blood pressure and/or cardiovascular disease risk threshold should antihypertensive drug treatment be initiated for adults with hypertension?
Intervention(s)	Treatment initiation at different thresholds
Comparison(s)	Compared against each other (comparing different blood pressure and/or cardiovascular risk thresholds) Also within each other
Outcomes	Assessed at 12 months or more (using final endpoint) Critical <ul style="list-style-type: none">• All-cause mortality• Health-related quality of life• Stroke (ischaemic or haemorrhagic)• Myocardial infarction (MI) Important <ul style="list-style-type: none">• Heart failure needing hospitalisation• Vascular procedures (including both coronary and carotid artery procedures)• Angina needing hospitalisation• Side effect 1: Acute kidney injury• Side effect 2: New onset diabetes• Side effect 3: Changes in estimated Glomerular filtration rate (eGFR) or creatinine• Side effect 4: Hypotension (dizziness)

	<ul style="list-style-type: none">• [Combined cardiovascular disease outcomes in the absence of MI and stroke data]• [Coronary heart disease outcome in the absence of MI data]
Study design	Systematic reviews (SR), randomised control trials (RCT), Non-randomised study (NRS)

1.4 1 Methods and process

- 2 This evidence review was developed using the methods and process described in
3 Developing NICE guidelines: the manual.¹¹⁷ Methods specific to this review question are
4 described in the review protocol in appendix A.
- 5 Declarations of interest were recorded according to NICE's 2018 conflicts of interest policy.

1.5 6 Clinical evidence

1.5.1 7 Included studies

- 8 One individual patient data (IPD) meta-analysis,¹⁴³ 1 longitudinal cohort study¹³⁶ and 2
9 systematic reviews were included in the review;^{36, 90} these are summarised below (Table 2).
10 Evidence from these studies is summarised in the clinical evidence summary below (Table
11 4).
- 12 Risk of bias of the studies included in the IPD meta-analysis and systematic reviews had
13 been measured using the Cochrane risk of bias tool, which we incorporated into our GRADE
14 assessment for overall quality assessment per outcome. Where risk of bias assessments
15 were available for some, but not all, studies included within one of the systematic reviews,
16 additional risk of bias assessments were conducted and integrated with the existing
17 assessments per outcome, as per section 2.3.4.1 of the methods chapter. Where risk of bias
18 was not available for the studies included within one of the systematic reviews, the ROBIS
19 checklist was incorporated into the GRADE assessments for overall quality assessment per
20 outcome.
- 21 See also the study selection flow chart in appendix C, study evidence tables in appendix D,
22 forest plots in appendix E and GRADE tables in appendix F.
- 23

1.5.2 Summary of clinical studies included in the evidence review

Table 2: Summary of studies included in the evidence review

Study	Intervention and comparison	Population	Outcomes	Comments
Brunström 2018 ³⁶ (systematic review of RCTs)	Systolic blood pressure thresholds: <140 (n=68,966) 140–159 (n=43,889) ≥160 mmHg (n=79,940) Treatment versus no treatment	Adults with hypertension, with and without diabetes (n=192,795)	At 4 years: All-cause mortality Stroke Coronary heart disease Heart failure	Study downgraded for very serious indirectness as the population included coronary artery disease (CAD), mixed CVD and post-stroke. Also, the review included studies that pooled low intensity treatment and no treatment arms (16% of study population).
Law 2009 ⁹⁰ (systematic review of RCTs and non-randomised studies)	Diastolic blood pressure thresholds: >80 (n=42,599) 80–84 (n=37,516) 85–89 (n=39,731) 90–94 (n=38,646) >95 (n=6,195) Treatment versus no treatment.	Adults with hypertension, with and without diabetes (n=464,000; multiple comparisons, actual number of participants included within the diastolic thresholds analysis: n=164,687)	At 4 years: Stroke Coronary heart disease	Study downgraded for very serious indirectness as the population included CAD, mixed CVD and post-stroke. Also, review included studies that pooled low intensity treatment and no treatment arms.
Sheppard 2018 ¹³⁶ (cohort study)	Systolic blood pressure threshold of 140–159 mmHg with a low cardiovascular risk (mean cardiovascular risk threshold of 8%; QRISK2) Treatment versus no treatment	Adults with hypertension, without diabetes (n=38,286)	At 5.8 years: Mortality Stroke Heart failure MI Non-MI acute coronary syndrome Hypotension Acute Kidney Injury	Participants with previous cardiovascular events were excluded from the trial 7,720 participants (20.2%) included in the main analysis had a previous risk score recorded, and an additional 9,096 (23.8%) had available risk factor information to calculate a QRISK2 score. For the remaining 21,050 (56%), cardiovascular risk

Study	Intervention and comparison	Population	Outcomes	Comments
				<p>was estimated by inserting age- and sex-standardised mean cholesterol values and Townsend scores from the Health Survey for England into the algorithm to replace missing data.</p> <p>Downgraded for indirectness because 41.6% of the non-treatment arm were on treatment at some point in the trial. Some QRISK2 inputs were also not available in all participants and were imputed (estimated 56% of the population had some form of imputation). The mean diastolic blood pressure was also 88.5 (standard deviation [SD] 5.2) mmHg less than the threshold for stage 1 hypertension.</p>
Sundstrom 2015 ¹⁴³ (IPD)	Systolic blood pressure threshold of 140–159 mmHg Treatment versus no treatment	Adults with hypertension and type 2 diabetes (n=6361)	At 4.4 years: All-cause mortality Stroke Heart failure	<p>RCTs where at least 80% of participants had grade 1 hypertension and had no previous cardiovascular disease were included.</p> <p>To note that risk of bias for individual studies included within the review was not available. The ROBIS checklist (assessing the quality of the systematic review itself) was therefore incorporated into the GRADE assessments for overall quality assessment per outcome.</p>

(a) There was a big overlap in the included studies in both these reviews; therefore, outcomes were only extracted once to avoid double counting.

See appendix D for full evidence tables.

1.5.3 1 Excluded studies

- 2 There were 4 systematic reviews using individual patient data (IPD) identified for this review. IPDs would be preferentially included over other
- 3 systematic reviews if directly relevant to the review protocol, as they use raw data from each participant across all the included trials as
- 4 opposed to summary data. However, due to substantial deviations from the protocol for this review, 3 of these IPDs were excluded, as were 3
- 5 systematic reviews (see table below for detailed exclusion reasons).

6 **Table 3: Excluded reviews**

Systematic review	Exclusion reasons
Blood Pressure Lowering Trialists Collaboration IPD ¹⁴⁴	<ul style="list-style-type: none"> • The study used a customised risk calculator to stratify participants into risk groups. It was unclear how risk was calculated and whether the groups were similar to validated risk tools such as Framingham, QRISK2 or 3. The risk calculator also used previous cardiovascular events, which is not considered a useful measure and is not included in any validated risk tools. • The cardiovascular risk groups compared within each category also differed within each outcome, which made results difficult to interpret. • The population didn't match this review protocol's requirements: unclear if participants were already treated or on other treatment (55.9% had previous treatment) and unclear if baseline cardiovascular risk was measured while participants were untreated. 39.1% of the population had diabetes with no detail of whether this was type 1 or type 2 diabetes. • Pooled trial data of 'less intensive arms' with placebo, which was an exclusion criterion on the protocol for this review. • No minimum trial duration inclusion criterion, whereas this review had a requirement of trials with a minimum duration of 12 months. • The trialists used meta-regression with the observed 5-year risks to extend all results to 5 years; the average follow up time was not stated.
Blood Pressure Lowering Trialists Collaboration IPD ⁴⁴	<ul style="list-style-type: none"> • For the blood pressure categories outlined in the protocol for this review, the only available outcome was major cardiovascular events. This composite outcome was included in the review protocol but was only to be included if individual cardiovascular event outcomes were not available. This is because these outcomes were considered to be more informative. • Individual morbidity and mortality outcomes were given at systolic blood pressure thresholds of above 140 mmHg and below 140 mmHg. Above 140 mmHg was not a threshold listed in the protocol and would not have informed recommendations as this encompasses stage 1 and stage 2 hypertension. The below 140 mmHg comparison was considered for inclusion but 58.9% had other cardiovascular disease and were taking medication for secondary prevention.

Systematic review	Exclusion reasons
	<ul style="list-style-type: none"> • Baseline characteristics were not stated, and the IPD included participants that were already treated; it was unclear if baseline blood pressure had been measured while participants were untreated.
Asayama 2009 IPD ¹⁷	<ul style="list-style-type: none"> • Study carried out in Japan and considered not to be applicable to the UK population due to the known differences in antihypertensive treatment and prevalence of cardiovascular events, that is, different antihypertensive drugs administered and lower dosages of treatment given than in the UK. The prevalence of stroke and heart failure are higher in Japan, which were the only included outcomes in the IPD. In addition, the incidence of myocardial infarction tends to be lower in Japanese people with hypertension, which is an outcome of interest for this guideline. • The comparisons included were not in line with this review protocol. Rather than comparing treatment versus no treatment at each blood pressure threshold, the IPD compared treatment at each threshold versus no treatment in the 'optimal' below 120 mmHg systolic blood pressure category. This would have substantially influenced the results. • Unclear from the IPD whether baseline blood pressure was measured before treatment was initiated.
Brunström 2016 ³⁵	<ul style="list-style-type: none"> • There is an overlap in included studies included in this review with those included in Sundstrom 2015.¹⁴³ The IPD (Sundstrom) was therefore preferentially included.
Emdin ⁴⁹	<ul style="list-style-type: none"> • There is an overlap in included studies included in this review with those included in Sundstrom 2015.¹⁴³ The IPD (Sundstrom) was therefore preferentially included. • Stratified by above 140 mmHg and below 140 mmHg; above 140 mmHg was not a threshold listed in the protocol and would not have informed recommendations as this encompasses stage 1 and stage 2 hypertension. 65% of the population in the below 140 mmHg threshold had other cardiovascular disease and were taking antihypertensive medication for secondary prevention
Ettehad ⁵¹	<ul style="list-style-type: none"> • Majority of participants had coronary heart disease and 15–40% had heart failure

1 See the full excluded studies list in appendix I.

1.5.4 1 Quality assessment of clinical studies included in the evidence review

2 **Table 4: Clinical evidence summary: Treatment versus no treatment at systolic blood pressure thresholds (with and without type 2**
3 **diabetes)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Treatment versus no treatment (95% CI)
All-cause mortality <140 mmHg	68,816 (1 study) 4 years	LOW ¹ due to indirectness	RR 0.98 (0.9 to 1.07)		[4,897 events in 68, 16 people] ⁵
All-cause mortality 140–159 mmHg	41,049 (1 study) 4 years	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.87 (0.75 to 1.01)	56 per 1,000 ³	7 fewer per 1,000 (from 14 fewer to 1 more)
All-cause mortality ≥160 mmHg	79,900 (1 study) 4 years	LOW ¹ due to indirectness	RR 0.93 (0.87 to 0.99)	81 per 1,000 ³	6 fewer per 1,000 (from 1 fewer to 11 fewer)
Stroke <140 mmHg	62,751 (1 study) 4 years	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.85 (0.68 to 1.06)	30 per 1,000 ⁴	4 fewer per 1,000 (from 10 fewer to 2 more)
Stroke 140–159 mmHg	41,641 (1 study) 4 years	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.86 (0.72 to 1.03)	42 per 1,000 ⁴	6 fewer per 1,000 (from 12 fewer to 1 more)
Stroke ≥160 mmHg	79,900 (1 study) 4 years	LOW ¹ due to indirectness	RR 0.69 (0.6 to 0.79)	62 per 1,000 ⁴	19 fewer per 1,000 (from 13 fewer to 25 fewer)
Coronary heart disease <140 mmHg	62,617 (1 study) 4 years	LOW ¹ due to indirectness	RR 0.98 (0.88 to 1.09)	66 per 1,000 ⁴	1 fewer per 1,000 (from 8 fewer to 6 more)
Coronary heart disease 140–159 mmHg	42,543 (1 study) 4 years	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.86 (0.76 to 0.97)	34 per 1,000 ⁴	5 fewer per 1,000 (from 1 fewer to 8 fewer)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Treatment versus no treatment (95% CI)
Coronary heart disease ≥ 160 mmHg	78,617 (1 study) 4 years	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.86 (0.78 to 0.95)	56 per 1,000 ⁴	12 fewer per 1,000 (from 8 fewer to 15 fewer)
Heart failure <140 mmHg	60,879 (1 study) 4 years	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.88 (0.78 to 0.99)	Moderate	[2,261 events in 60,879 people] ⁵
Heart failure 140–159 mmHg	35,254 (1 study) 4 years	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.87 (0.73 to 1.04)	Moderate	[1,113 events in 35,254 people] ⁵
Heart failure ≥ 160 mmHg	23,395 (1 study) 4 years	LOW ¹ due to indirectness	RR 0.53 (0.42 to 0.67)	Moderate	[520 events in 23,395 people] ⁵

¹Downgraded by 1 increment due to population or outcome indirectness or by 2 increments for both population and outcome indirectness
²Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs
³Control group risk not reported; values extrapolated from Bulpitt 1988³⁸
⁴Control group risk not reported; values extrapolated from Law 2009⁹⁰
⁵Control group risk not reported; therefore, absolute risk could not be calculated: no data was available that values could be extrapolated from.

1
2 **Table 5: Clinical evidence summary: Treatment versus no treatment at systolic blood pressure thresholds (type 2 diabetes)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with No treatment (diabetes)	Risk difference with Treatment (95% CI)
All-cause mortality 140–159 mmHg	6,334 (1 study) 4.4 years	MODERATE¹ due to imprecision	RR 0.76 (0.64 to 0.9)	90 per 1,000	22 fewer per 1,000 (from 9 fewer to 32 fewer)
All-cause mortality 140–159 mmHg	6,334 (1 study) 4.4 years	MODERATE ¹ due to imprecision	RR 0.76 (0.64 to 0.9)	90 per 1,000	22 fewer per 1,000 (from 9 fewer to 32 fewer)
Stroke 140–159 mmHg	5,897 (1 study) 4.4 years	MODERATE ¹ due to imprecision	RR 0.8 (0.68 to 0.95)	94 per 1,000	19 fewer per 1,000 (from 5 fewer to 30 fewer)
Heart failure 140–159 mmHg	5,629 (1 study) 4.4 years	MODERATE ¹ due to imprecision	RR 0.78 (0.56 to 1.09)	28 per 1,000	6 fewer per 1,000 (from 12 fewer to 2 more)

¹ Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

3
4 **Table 6: Clinical evidence summary: Effects of treatment versus no treatment at diastolic blood pressure thresholds (with and without type 2 diabetes)**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Treatment versus no treatment (95% CI)
Stroke <80 mmHg	42,599 (1 study) 4 years	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.74 (0.68 to 0.82)	45 per 1,000	12 fewer per 1,000 (from 8 fewer to 15 fewer)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Treatment versus no treatment (95% CI)
Stroke 80–84 mmHg	37,516 (1 study) 4 years	VERY LOW ^{1,2} due to indirectness, imprecision	RR 0.76 (0.67 to 0.87)	28 per 1,000	7 fewer per 1,000 (from 4 fewer to 9 fewer)
Stroke 85–89 mmHg	39,731 (1 study) 4 years	LOW ¹ due to indirectness	RR 0.68 (0.62 to 0.75)	45 per 1,000	14 fewer per 1,000 (from 11 fewer to 17 fewer)
Stroke 90–94 mmHg	38,646 (1 study) 4 years	LOW ¹ due to indirectness	RR 0.63 (0.56 to 0.71)	33 per 1,000	12 fewer per 1,000 (from 9 fewer to 14 fewer)
Stroke >95 mmHg	6,195 (1 study) 4 years	LOW ¹ due to indirectness	RR 0.51 (0.41 to 0.63)	73 per 1,000	36 fewer per 1,000 (from 27 fewer to 43 fewer)

¹Downgraded by 1 or 2 increments due to population or outcome indirectness
²Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

1 Table 7: Clinical evidence summary: Treatment versus no treatment at systolic blood pressure threshold of 140-159mmHg at low cardiovascular risk (without type 2 diabetes) – non-randomised evidence

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects ³	
				Risk with No treatment (no diabetes)	Risk difference with Treatment (95% CI)
Mortality 140–159 mmHg	38,286 (1 study) 5.8 years	VERY LOW ² due to indirectness	HR 1.02 (0.88 to 1.18) ⁴	41 per 1,000	1 more per 1,000 (from 5 fewer to 7 more)
Stroke 140–159 mmHg	38,286 (1 study) 5.8 years	VERY LOW ^{1,2} due to, imprecision, indirectness	HR 0.97 (0.78 to 1.21) ⁴	15 per 1,000	0 fewer per 1,000 (from 3 fewer to 3 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects ³	
				Risk with No treatment (no diabetes)	Risk difference with Treatment (95% CI)
Myocardial Infarction 140–159 mmHg	38,286 (1 study) 5.8 years	VERY LOW ² due to indirectness	HR 1.00 (0.80 to 1.25) ⁴	15 per 1,000	0 fewer per 1,000 (from 3 fewer to 4 more)
Heart failure 140–159 mmHg	38,286 (1 study) 5.8 years	VERY LOW ^{1,2} due to imprecision, indirectness	HR 1.34 (0.96 to 1.87) ⁴	7 per 1,000	2 more per 1,000 (from 0 fewer to 6 more)
Non-MI acute coronary syndrome 140–159 mmHg	38,286 (1 study) 5.8 years	VERY LOW ^{1,2} due to imprecision, indirectness	HR 1.19 (0.74 to 1.91) ⁴	3 per 1,000	1 more per 1,000 (from 1 fewer to 3 more)
Hypotension 140–159 mmHg	38,286 (1 study) 5.8 years	VERY LOW ² due to indirectness	HR 1.69 (1.30 to 2.20) ⁴	8 per 1,000	6 more per 1,000 (from 3 more to 10 more)
Acute Kidney Injury 140–159 mmHg	38,286 (1 study) 5.8 years	VERY LOW ^{1,2} due to imprecision, indirectness	HR 1.37 (1 to 1.88) ⁴	8 per 1,000	3 more per 1,000 (from 0 more to 7 more)

¹Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.
²Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively.
³Absolute effects calculated by inputting raw event data from median follow up time into GRADE.
⁴Evidence based on one study that reported HRs with raw event data.

1 See appendix F for full GRADE tables.

2

1.6 1 Economic evidence

1.6.1 2 Included studies

3 No relevant health economic studies were identified.

1.6.2 4 Excluded studies

5 Four studies relating to this review question were identified but were excluded due to
6 applicability or methodological limitations.^{142,20,55,88} These are listed in appendix I, with
7 reasons for exclusion given.

8 See also the health economic study selection flow chart in appendix G.

1.6.3 1 Health economic modelling

2 Methods

3 The clinical evidence review identified evidence in different blood pressure thresholds, but no
4 evidence was identified relating to cardiovascular risk.

5 The committee agreed there was evidence to suggest relative treatment benefit in people
6 with stage 1 hypertension (Systolic BP 140–159 mmHg), in terms of reducing cardiovascular
7 events. But there was uncertainty about cost effectiveness in this population because the
8 same relative treatment benefit would lead to different absolute benefits in people with lower
9 cardiovascular risk compared to people with higher cardiovascular risk.

10 The current recommendations for treatment initiation amongst those with stage 1
11 hypertension incorporate a cardiovascular risk-based component, of 20%, in people without
12 target organ damage, established cardiovascular disease, renal disease, or diabetes. This
13 recommendation was based on consensus. The committee agreed that it was a high
14 modelling priority for this guideline update to evaluate whether only initiating drug treatment
15 in this population with a 10-year cardiovascular risk equivalent to 20% or greater was the
16 most cost effective option.


17 Therefore, the aim of the model was to investigate the cardiovascular risk level at which it is
18 cost effective to initiate antihypertensive drug treatment in people with stage 1 hypertension
19 without target organ damage, established cardiovascular disease, renal disease or diabetes.

20 A similar evaluation was recently undertaken as part of the NICE Cardiovascular disease:
21 risk assessment and reduction, including lipid modification (CG181)¹⁶ guideline update, and
22 it was agreed that it would be appropriate to take a similar approach for this guideline.

23 The model was a cost–utility analysis with a lifetime horizon comparing antihypertensive
24 treatment with no antihypertensive treatment in a population with stage 1 hypertension with a
25 base-case age of 60. The intervention and comparator were compared in 4 10-year QRISK2
26 cardiovascular risk subgroups to assess whether it is cost effective to use antihypertensive
27 drug treatment in each risk group: 5%, 10%, 15% and 20%. Men and women were also
28 compared separately. Additionally, other age groups were also evaluated: age 40, 50, 70 and
29 75.

30 The model structure was a Markov model with 1 year cycles. People begin in a ‘no
31 cardiovascular event’ state and could transition to 6 non-fatal cardiovascular event health
32 states of stable angina, unstable angina, myocardial infarction, transient ischaemic attack,
33 stroke and heart failure, as well as 2 fatal states of cardiovascular and non-cardiovascular
34 death. Each event state also had a respective post-event state where people move to in the
35 following cycle after an event. Repeat events were not modelled.

Figure 1: Model structure



Abbreviations: CVD: cardiovascular disease; HF: heart failure; MI: myocardial infarction; PES: post-event state; SA: stable angina; Str: stroke; TIA: transient ischaemic attack; UA: unstable angina. The death state can include cardiovascular or non-cardiovascular death.

1

2 The cardiovascular risk subgroups were predefined, and the risk of a first event was
3 determined by the distribution of this cardiovascular risk over the cardiovascular events in the
4 model, which varies by age and sex. The distribution of events was taken from the NICE
5 Lipids model. There was also an annual absolute increase in coronary heart disease risk that
6 was applied to the coronary heart disease events of stable angina, unstable angina, and
7 myocardial infarction. The same risk was applied to the other events depending on their
8 frequency relative to the coronary heart disease events. This was assumed to capture that
9 risk increases with age; therefore, that meant that beyond the 10-year period (as QRISK is a
10 10-year risk), cardiovascular risk would keep increasing linearly. This annual increase in
11 coronary heart disease risk was higher for men than for women.

12 Treatment effect in the base case was taken from a meta-analysis (Brunström 2018)³⁶
13 included in the clinical review from the stage 1 hypertension population, as that is the
14 population in the model. The same treatment effect was applied to all risk groups (which
15 would lead to different absolute impact), but acknowledging that this was data from mostly
16 intermediate/higher risk people. The risk of adverse events was taken from the targets
17 clinical review for this guideline. The costs considered included; drug treatment and
18 monitoring, adverse events (acute kidney injury [AKI] and falls), and treating cardiovascular
19 events. For full details see appendix A.

1 Results

- 2 The results of the model for the base-case age group (age 60) can be seen in Table 9.
3 Treatment was not cost effective at the 5% threshold. The probability of treatment being cost
4 effective at 10% for men and women was around 84–86%.

5 Table 8: Base case results (per person, discounted)

	Undiscounted life-years	Total Costs	Total QALYs	ICER (£)	Prob Tx CE at £20k	Undiscounted life-years	Total Costs	Total QALYs	ICER (£)	Prob Tx CE at £20k
	Male					Female				
5% risk										
No Tx	23.66	£2,925	12.93		55%	26.16	£3,362	13.17		55%
Tx	23.79	£4,129	12.98	21,849	45%	26.30	£4,561	13.23	21,727	45%
10% risk										
No Tx	22.84	£4,187	12.52		16%	25.24	£5,258	12.73		14%
Tx	23.03	£5,192	12.61	10,676	84%	25.46	£6,180	12.83	9,399	86%
15% risk										
No Tx	22.09	£5,366	12.14		7%	24.41	£7,016	12.33		5%
Tx	22.34	£6,194	12.26	6,491	93%	24.69	£7,700	12.46	5,103	95%
20% risk										
No Tx	21.40	£6,465	11.77		3%	23.67	£8,637	11.95		3%
Tx	21.70	£7,148	11.93	4,396	97%	23.98	£9,120	12.11	3,024	97%

6 Note that values shaded red are above the NICE cost effectiveness threshold of £20,000 per QALY

7 Abbreviations: CE = cost effective, 20k = £20,000, ICER = incremental cost effectiveness ratio, No Tx = No
8 treatment, QALYS = quality adjusted life-years, Tx = treatment.

9 Some work was undertaken to identify the minimum QRISK2 levels for someone aged 60
10 who is male or female in order to have some clinical context to interpret the risk thresholds
11 predicted by the model (see Table 9, column labelled 1, for those aged 60). These minimum
12 risk levels were found by using the QRISK2 online calculator – assuming a clinic systolic
13 blood pressure of 140 mmHg, a low total to HDL cholesterol ratio of 2.5, and all other
14 variables within the calculator were left blank. The minimum risk levels represent the
15 healthiest version of someone of a particular age and sex with stage 1 hypertension.

16 As the minimum QRISK2 risk levels identified for men and women aged 60 with stage 1
17 hypertension (8.5% for men and 5.3% for women) were higher than the risk levels predicted
18 by the model, above which treatment is cost effective, it would be cost effective to treat all
19 people aged 60 with stage 1 hypertension. The probability of treatment being cost effective at
20 the 5% level was around 50% for both sexes. However, as women tend to have a lower
21 calculated risk, if a woman aged 60 was at very low risk (that is, close to the QRISK2
22 minimum risk level of 5.3%), then there is likely to be just as much uncertainty on whether
23 treatment would be cost effective for that individual as whether no treatment would not be
24 cost effective.

25 Results from the other age subgroups showed that the younger the population, the lower the
26 risk level at which treatment becomes cost effective, as younger people have more time to
27 benefit from treatment. Comparing the risk thresholds predicted from the model for each age
28 group with the minimum risk levels calculated (see Table 9) showed that it was cost effective
29 to treat all ages with stage 1 hypertension except women aged 40 and 50, where the model

1 risk thresholds were higher than the minimum risk levels, as risk is very low in younger
2 women.

3

4 **Table 9: Summary of risk thresholds for all age groups**

Age	1) Minimum risk level from QRISK2	2) Risk threshold at which treatment becomes cost effective (from model)	Decision in clinical practice (a)
Male			
40	1.50%	0.83%	Treat all
50	4.00%	2.12%	Treat all
60	8.50%	5.39%	Treat all
70	16.40%	10.33%	Treat all
75	22%	12.07%	Treat all
Female			
40	0.90%	1.86%	Treat above 1.86% risk
50	2.30%	3.06%	Treat above 3.06% risk
60	5.30%	5.27%	Treat all
70	11.70%	7.99%	Treat all
75	17.00%	8.99%	Treat all

5 (a) Note: if the risk levels the model found were cost effective (column labelled 2) are lower than the minimum risk
6 level (column labelled 1), then it is cost effective to treat everyone at that age, regardless of risk; otherwise,
7 the model result is the lowest cost effective risk level.

8 It was acknowledged that the base-case analysis was a simplification of the reality in that
9 those who are initially untreated are unlikely to remain untreated their entire lives, as the
10 current recommendation lists various criteria that people with stage 1 hypertension can meet
11 that would make them eligible for treatment, which they may develop in the future as well as
12 potentially progressing to stage 2 hypertension. Because it was considered too complex to
13 capture how these underlying risk factors would change over time in the model, a sensitivity
14 analysis on differential treatment durations was undertaken. This involved testing arbitrary
15 time points at which people in the no treatment arm started treatment, in order to mimic that
16 people wouldn't stay untreated forever and to see how this would affect results. See Table 10
17 for results. For the base-case age group (age 60), the assumptions around differential
18 treatment duration that were tested did not change the results because all risk thresholds
19 identified were similar and were still lower than the minimum risk values from the QRISK2
20 calculator.

21 Testing differential treatment durations and whether that impacted the main conclusions for
22 the other age groups, showed that in men it wasn't cost effective anymore to treat all men
23 aged 40 and 50 if they were likely to develop other reasons for going onto treatment in
24 shorter durations of time (1–10 years). For women, the conclusions did not change when
25 differential treatment durations were tested.

26 **Table 10: Differential treatment duration results for all ages**

Years before meeting other criteria for treatment	Risk threshold				
	Age 40	Age 50	Age 60	Age 70	Age 75
MALES					
1	4.4%	4.3%	6.5%	11.1%	12.4%
5	3.7%	3.7%	5.8%	10.9%	12.1%

10	2.8%	2.9%	5.1%	-	-
20	1.3%	2.2%	-	-	-
Never (base case)	0.8%	2.1%	5.4%	10.3%	12.1%
Minimum risk level	1.5%	4.0%	8.5%	16.4%	22.3%
FEMALES					
1	2.7%	3.0%	5.0%	7.9%	8.5%
5	2.4%	2.8%	4.9%	8.0%	8.5%
10	2.1%	2.5%	4.7%	-	-
20	1.7%	2.8%	-	-	-
Never (base case)	1.9%	3.1%	5.3%	8.0%	9.0%
Minimum risk level	0.9%	2.3%	5.3%	11.7%	17.0%

1 The columns show the risk thresholds for the different age groups. The rows show the differential treatment
2 durations tested, and also the results of the base case analysis for each age group (that is, where a lifetime of
3 treatment was compared to a lifetime of no treatment). Additionally the minimum risk values from the QRISK2 are
4 also presented with orange text. Cells that are orange show where it is cost effective to treat everyone at that age
5 because the risk threshold the model predicted is lower than the minimum risk level.

6 Various sensitivity analyses were undertaken. Varying treatment effect to make it more or
7 less favourable was undertaken probabilistically for all age groups. The model was very
8 sensitive to more favourable treatment effect, and treatment became cost effective at the 5%
9 risk level even for those aged 75. Other sensitivity analyses were only undertaken
10 deterministically for the 60 year old group. Inputs that changed the results by making
11 treatment cost effective even at 5% risk included smaller drug costs, higher health state
12 costs, nurses undertaking monitoring, not including adverse events, having higher annual
13 cardiovascular (CV) risk increases for women, and lower utilities. Various inputs that would
14 bias against treatment (like increasing cost) made treatment less cost effective but hardly
15 ever to the extent that the 10% risk subgroup was not cost effective.

16 Limitations of the model were that repeat events were not modelled, which made the model
17 more conservative towards treatment. The model was also conservative in other ways such
18 as there are some events the model hasn't captured that may be avoided by taking
19 antihypertensive treatment. The model used the average long-term mortality ratios that may
20 mean mortality immediately following an event has been underestimated. Some inputs have
21 been taken from previous models and could be considered out of date, but these were
22 checked with the committee who concluded it would be difficult to find more up-to-date data.
23 Additionally, the assumption that people in the no treatment arm would remain on no
24 treatment was a simplification, but this has been addressed through a sensitivity analysis.
25 The variability in risk over time has not been captured due to limited data; thus, a more linear
26 approach was taken. Adherence to treatment has also not been included, which would
27 reduce the effectiveness of treatment on a population level if adherence is poor. However,
28 overall, it is generally accepted that antihypertensive treatment is very cost effective. On
29 balance, the model was felt to be conservative towards treatment.

1.6.40 Resource costs

31 Initiating drug treatment to different blood pressure or risk thresholds will involve drug and
32 monitoring costs and may have varying cost offsets in terms of cardiovascular events
33 avoided depending on the severity of the population. These trade-offs were explored in detail
34 in the economic modelling.

1.7 1 Evidence statements

1.7.1 2 Clinical evidence statements

1.7.1.1 3 Treatment versus no treatment as systolic blood pressure thresholds (with and 4 without type 2 diabetes)

5 Below 140 mmHg threshold

6 Low quality evidence from 1 study with 62,617–68,816 participants showed no clinically
7 important difference between starting treatment at below 140 mmHg and not starting
8 treatment for all-cause mortality or coronary heart disease at 4 years. Very low quality
9 evidence from 1 study with 60,879 participants showed no clinically important difference for
10 stroke or heart failure at 4 years.

11 140–159 mmHg threshold

12 Very low quality evidence from 1 study with 35,254–42,543 participants showed a clinically
13 important benefit of starting treatment at 140–159 mmHg for all-cause mortality, stroke,
14 coronary heart disease and heart failure at 4 years.

15 160 mmHg or above threshold

16 Low quality evidence from 1 study with 79,900 participants showed a clinically important
17 benefit of starting treatment at 160 mmHg or above for all-cause mortality and stroke at 4
18 years. Very low quality evidence from 1 study with 78,617 participants showed a clinically
19 important benefit of starting treatment at this threshold for reducing occurrence of coronary
20 heart disease at 4 years. Low quality evidence from 1 study with 23,395 participants showed
21 a clinically important benefit of starting treatment in terms of reducing occurrence of heart
22 failure at 4 years.

1.7.1.2 3 Treatment versus no treatment as 140–159 mmHg systolic blood pressure thresholds 24 (type 2 diabetes)

25 Moderate quality evidence from 1 study with 5,629–6,334 participants showed a clinically
26 important benefit of starting treatment at 140–159 mmHg in terms of all-cause mortality,
27 stroke and heart failure at 4.4 years.

1.7.1.3 8 Treatment versus no treatment as diastolic blood pressure thresholds (with and 29 without type 2 diabetes)

30 Below 80 mmHg threshold

31 Very low quality evidence from 1 study with 42,599 participants showed a clinically important
32 benefit of starting treatment at a diastolic blood pressure of below 80 mmHg in terms of
33 stroke occurrence at 4 years.

34 80–84 mmHg threshold

35 Very low quality evidence from 1 study with 37,516 participants showed a clinically important
36 benefit of starting treatment at a diastolic blood pressure of 80–84 mmHg in terms of stroke
37 occurrence at 4 years.

1 **85–89 mmHg threshold**

2 Low quality evidence from 1 study with 39,731 participants showed a clinically important
3 benefit of starting treatment at a diastolic blood pressure of 85–89 mmHg in terms of stroke
4 occurrence at 4 years.

5 **90–94 mmHg threshold**

6 Low quality evidence from 1 study with 38,646 participants showed a clinically important
7 benefit of starting treatment at a diastolic blood pressure of 90–94 mmHg in terms of stroke
8 occurrence at 4 years.

9 **95 mmHg or above threshold**

10 Low quality evidence from 1 study with 6,195 participants showed a clinically important
11 benefit of starting treatment at a diastolic blood pressure of 95 mmHg or above in terms of
12 stroke occurrence at 4 years.

13 **1.7.1.43 Treatment versus no treatment at 140–159 mmHg systolic blood pressure thresholds**
14 **(without type 2 diabetes, low cardiovascular risk)**

15 Very low quality evidence from 1 study with 38,286 participants showed no clinically
16 important difference for starting treatment at 140–159 mmHg compared to not starting
17 treatment for stroke, myocardial infarction, heart failure, non-myocardial infarction acute
18 syndrome and acute kidney injury at 5.8 years. Very low to low quality evidence from 1 study
19 with 38,286 participants showed a clinically important harm of starting treatment at this
20 threshold for mortality and hypotension at 5.8 years.

1.7.21 **Health economic evidence statements**

22 One original cost–utility analysis found that antihypertensive drug treatment was cost
23 effective compared to no antihypertensive drug treatment for treating hypertension in people
24 aged 60 with a 10% 10-year cardiovascular risk (ICER in men: £10,676 per QALY gained;
25 ICER in women: £9,399 per QALY).

1.8 **Recommendations**

27 For advice on shared decision-making for medicines, see the information on patient decision
28 aids in NICE's guideline on medicines optimisation. To support adherence and ensure that
29 people with hypertension make the most effective use of their medicines, see NICE's
30 guideline on medicines adherence.

31 C1. Discuss with the person their preferences for treatment before starting antihypertensive
32 drug treatment. Continue to offer lifestyle advice and support them to make lifestyle
33 changes whether or not they choose to start antihypertensive drug treatment.

34 C2. Offer antihypertensive drug treatment in addition to lifestyle advice (see recommendation
35 1.4.1) to adults aged under 80 with persistent stage 1 hypertension who have 1 or more
36 of the following:

- 37 • target organ damage
- 38 • established cardiovascular disease
- 39 • renal disease
- 40 • diabetes
- 41 • an estimated 10-year risk of cardiovascular disease of 10% or more. **[2019]**

- 1 C3. Offer antihypertensive drug treatment to adults of any age with persistent stage 2
2 hypertension. Use clinical judgement for people with frailty or multimorbidity (see also
3 NICE's guideline on multimorbidity). [2019]
- 4 C4. Consider antihypertensive drug treatment in addition to lifestyle advice for younger adults
5 with stage 1 hypertension and an estimated 10-year risk below 10%. Bear in mind that
6 10-year cardiovascular risk may underestimate the lifetime probability of developing
7 cardiovascular disease. [2019]
- 8 C5. Consider starting antihypertensive drug treatment for people aged over 80 with stage 1
9 hypertension. Use clinical judgement for people with frailty or multimorbidity (see also
10 NICE's guideline on multimorbidity). [2019]
- 11 C6. For adults aged under 40 with hypertension, consider seeking specialist evaluation of
12 secondary causes of hypertension and a more detailed assessment of the long-term
13 balance of treatment benefit and risks. [2019]

1.8.114 Research recommendations

- 15 RR1. In adults aged under 40 with hypertension (with or without type 2 diabetes), what are
16 the appropriate risk and blood pressure thresholds for starting treatment?
- 17 See also the rationale in appendix J.

1.9 18 The committee's discussion of the evidence

1.9.119 Interpreting the evidence

1.9.1.20 The outcomes that matter most

21 The committee considered all-cause mortality, quality of life, stroke and myocardial infarction
22 to be critical outcomes for decision-making. Heart failure, vascular procedures, angina and
23 specific adverse events such as reduction in estimated glomerular filtration rate (eGFR) were
24 also considered important for decision-making.

25 Most of the evidence identified covered outcomes of mortality, stroke and heart failure. No
26 adverse event data were identified. Data on occurrence of coronary heart disease were used
27 in the absence of evidence for myocardial infarction.

1.9.1.28 The quality of the evidence

29 The quality of the clinical effectiveness evidence was low to very low. Although risk of bias
30 was generally low, serious indirectness and imprecision resulted in lower evidence quality
31 and made the evidence base more difficult to interpret. Most of the RCTs included in this
32 review included some participants who were beyond the scope of this guideline, such as
33 people with moderate to severe chronic kidney disease (CKD) and people with previous
34 cardiovascular events. This was apparent at treatment initiated at clinic systolic blood
35 pressure thresholds of less than 140 mmHg. The committee agreed that at this threshold, not
36 many trials had been conducted to investigate the effectiveness of antihypertensive
37 medication in those without diabetes, chronic kidney disease or previous cardiovascular
38 events, and as a consequence, the evidence at this threshold was considered indirect. To
39 ensure the evidence identified was applicable to the review question, studies that had an
40 indirect population greater than 20% were excluded.

41 There was no evidence available for people with hypertension without type 2 diabetes;
42 instead the evidence included was a mixed population. There was also no evidence available
43 comparing treatment at different cardiovascular risk levels.

1.9.1.3 1 Committee discussion of the evidence

2 Mixed populations including people with and without type 2 diabetes

3 The committee discussed the evidence for initiating treatment at different systolic blood
4 pressure thresholds in a mixed population, which included participants with primary
5 hypertension and with or without type 2 diabetes. Data were not available for people without
6 type 2 diabetes and hypertension alone as a distinct population, so the evidence was
7 interpreted for both groups together. The committee noted that it was difficult to interpret
8 evidence for treatment versus no treatment at a clinic blood pressure threshold below 140
9 mmHg. Because the committee was not aware of data based only on a primary prevention
10 population in this group, it assumed that the data were likely to be based on people who had
11 a previous cardiovascular event or chronic kidney disease. The data was therefore difficult to
12 interpret to inform recommendations for primary prevention of cardiovascular events. The
13 committee considered that people who had previously had a cardiovascular event would be
14 at a higher risk of having further events; therefore, these people could benefit from treatment
15 more, and these data could be overestimating the effect of treatment.

16 Regardless of this, there was no clinically important benefit for all-cause mortality when
17 initiating treatment at less than 140 mmHg, and the committee agreed that there was no
18 benefit of treating people at this level. The committee also discussed evidence for
19 occurrence of stroke in people with a blood pressure of less than 140 mmHg, which
20 demonstrated that there were 4 fewer strokes per 1,000 people in the treated group
21 compared to the untreated group. The committee agreed this was not an adequate clinical
22 benefit to justify treating all people with a systolic blood pressure of less than 140 mmHg. In
23 addition, there was no clinically important benefit of treatment at this threshold for reducing
24 coronary heart disease.

25 The committee found the data on occurrence of heart failure uninformative. Although there
26 was a clinical benefit of treatment at all blood pressure thresholds, this was based just on the
27 risk ratio without absolute event rates. As a result, the committee could not be as sure of the
28 effect without the actual number of events that occurred. The committee also considered that
29 the population included in the less than 140 mmHg group would have included people that
30 had previous heart failure or coronary artery disease. This meant that the evidence in this
31 group could be overestimating the efficacy of treatment. The committee could not determine
32 the real importance of this treatment without the absolute event rates within each arm. The
33 committee agreed there was no benefit of treating people with a systolic blood pressure less
34 than 140 mmHg, particularly when the proportion of participants with established
35 cardiovascular disease is taken into account.

36 The committee agreed that there was a clinically important benefit of treating people with a
37 clinic blood pressure of 140–159 mmHg and greater than 160 mmHg. This was based on
38 evidence for all-cause mortality, stroke and coronary heart disease. This was in a population
39 believed to be of moderate cardiovascular risk given the average age and blood pressure of
40 the study population. It could be argued that any mortality avoided should be considered a
41 benefit; however, what is also important in this review is the relation of the outcomes
42 between different blood pressure groups. Because absolute event rates were not available
43 for all outcomes, the committee found that looking at the relative risks of the different groups
44 simultaneously to infer a pattern was useful, in order to identify if there was a threshold at
45 which there is no (or less of a) treatment benefit. When considering the all-cause mortality
46 evidence in this way, the committee agreed that there was a benefit of treating people with a
47 systolic blood pressure above 140 mmHg. For the data on stroke and coronary heart
48 disease, the committee agreed that the evidence demonstrated benefit in treating groups
49 with a blood pressure of 140–159 mmHg and greater than 160 mmHg. An observational
50 study found treating people with stage 1 hypertension who were labelled as low risk (based
51 on inclusion criteria not formal assessment) did not provide any benefit in terms of reduction
52 in cardiovascular events but did lead to harms. The committee acknowledged that this was

1 lower quality evidence, but agreed that it did highlight there is uncertainty around the
2 effectiveness (and hence cost effectiveness) of treatment in lower risk groups amongst those
3 with stage 1 hypertension (whereas the previous guideline recommendation focused on
4 treating those at higher risk of cardiovascular events). The committee agreed that this
5 evidence did not answer this question fully, as there was no clinical evidence identified in
6 specific risk groups.

7 Taking the body of evidence into account, the committee was not convinced that a change in
8 guidance to treat below stage 1 hypertension was warranted. The committee kept in mind
9 that any change in these recommendations would need to be based on high quality
10 evidence, and it was not convinced that the systematic reviews included in this review
11 answered the review question fully, or that the outcomes were high enough quality, to
12 warrant any change in practice. Regardless of this, the evidence did not contradict current
13 recommendations. However, it did raise the question of whether all people with stage 1
14 hypertension should be treated.

15 For the evidence informing the outcomes for treating at different diastolic blood pressure
16 thresholds, the committee agreed that as there was no clear gradation of risk in the control
17 groups (for example, the control group event rate was lower in the 90–94 mmHg group than
18 it was in the 85–89 mmHg group). This did not lead to confidence in the results, as it is
19 expected that risk would increase as diastolic blood pressure increases. The committee
20 agreed it was difficult to make a decision based on diastolic blood pressure alone, as people
21 with low diastolic blood pressure tend to have the highest systolic blood pressure. It was
22 unclear what the systolic blood pressure level was within each group, and as a result, the
23 data were difficult to interpret. The committee therefore agreed that this evidence would not
24 change recommendations on diastolic blood pressure thresholds.

25 Patients with hypertension but without type 2 diabetes

26 The evidence showed a harm of treatment for mortality at a clinical systolic blood pressure of
27 140-159mmHg, because any difference in mortality was considered clinically important. The
28 evidence also showed clinically important harm of treatment in relation to hypotension, with 6
29 more hypotension events per 1000 and a HR of 1.69. There was no difference in stroke, MI
30 events, heart failure, acute coronary syndromes or acute kidney injury. The committee found
31 it difficult to interpret this evidence, due to the considerable uncertainty around each effect
32 estimate. The evidence therefore showed that the benefit of treating people with stage 1
33 hypertension at lower blood pressure and risk thresholds was uncertain. The mean
34 cardiovascular risk score (QRISK2) within the population was approximately 8%, although
35 the methods for calculating actual risk involved some imputation and therefore was limited in
36 its ability to accurately define the population at a particular risk threshold. Furthermore,
37 41.6% of participants in the non-treatment arm were on antihypertensive treatment at some
38 point in the trial, which could have influenced the effect sizes. Taking all of this into account,
39 the committee agreed that the evidence for treating people at lower risk with type 2 diabetes
40 and stage 1 hypertension was limited.

41

42 **People with type 2 diabetes**

43 The committee discussed the evidence for antihypertensive treatment for people with type 2
44 diabetes and stage 1 hypertension. The evidence for people with type 2 diabetes was very
45 low quality due to indirectness and imprecision, and because the evidence was based on
46 one cohort study. It agreed there was a clear benefit of treatment at a clinic blood pressure
47 of greater than 160/100mmHg for all-cause mortality, stroke and heart failure as patients with
48 type 2 diabetes would be at higher risk than those with hypertension alone. The evidence for
49 the 140-159mmHg studies showed that the clearest signal of benefit was for all-cause
50 mortality and stroke, with 22 fewer deaths and 19 fewer strokes per 1000 respectively.

1 Although no evidence was identified for the treatment of people with a clinic systolic blood
2 pressure of less than 140 mmHg, the committee was aware of a number of RCTs and
3 systematic reviews that reported no benefit of treating this group, even though they included
4 trials that recruited people at higher risk of events than those covered in this guideline, for
5 example by requiring the presence of target organ damage such as albuminuria or additional
6 cardiovascular risk factors; so it would be expected for the treatment benefit to be higher.
7 The committee therefore agreed that there was no evidence to suggest a different threshold
8 for people with hypertension and diabetes than without diabetes. This is a small change from
9 the diabetes guideline; the previous recommendations for people with type 2 diabetes
10 (NG28) suggested initiation of antihypertensive medication if lifestyle interventions alone did
11 not reduce blood pressure to below 140/80 mmHg or 130/80 mmHg in the presence of
12 kidney, cerebrovascular or eye disease. Evidence for lower treatment initiation thresholds in
13 people with type 2 diabetes was limited within this review, with evidence available for
14 treatment initiation above 140/90mmHg only and limited to patients with hypertension. The
15 committee was aware of some evidence to suggest that lower blood pressure thresholds did
16 not reduce the rate of cardiovascular events. The previous recommendations for people with
17 type 2 diabetes (NG28) were based on 2 small studies in people without hypertension.
18 Furthermore, these 2 studies were not designed to measure the benefit of treatment in
19 people who already had target organ damage but rather the studies predominantly assessed
20 the incidence of target organ damage based on a target diastolic blood pressure. The
21 committee therefore felt that there was insufficient evidence to recommend a different blood
22 pressure treatment threshold for this subgroup. Discussion of the appropriate blood pressure
23 target for patients with diabetes and significant albuminuria or other target organ damage
24 was outside the scope of this guideline.

1.9.25 Cost effectiveness and resource use

26 No published economic evidence was identified for this question.

27 The clinical review identified some evidence comparing treatment versus no treatment in
28 groups with different levels of systolic blood pressure. This showed that treatment was
29 generally clinically effective at reducing cardiovascular events in a mixed primary prevention
30 population with stage 2 hypertension. The committee also concluded that there was
31 insufficient clinical evidence to support initiation of drug treatment below the current definition
32 of stage 1 hypertension and noted that there is a lack of primary prevention studies in people
33 with blood pressure <140 mmHg and the evidence found in this group was likely to contain
34 some secondary prevention populations.

35 For those with stage 1 hypertension, the RCT evidence from the review showed that there
36 was some clinical benefit to treating this population, although the committee noted that this is
37 likely to be in intermediate or higher risk individuals based on the average characteristics and
38 the lack of published RCT data on low risk individuals. An observational study that was
39 included in this stage 1 population, specifically in lower risk individuals, suggested that
40 treatment has limited benefit but does have harms. As these studies are in different CV risk
41 populations, it confirmed to the committee that there is uncertainty around treatment effect in
42 different risk groups. The current recommendations for treatment initiation in those with stage
43 1 hypertension incorporate a cardiovascular risk-based component (of 20%), which was
44 based on consensus. Given this, and also that the clinical evidence showed some benefit to
45 treatment in the stage 1 group (but this was likely to be in people with intermediate or higher
46 risk), the committee agreed that it was a high modelling priority for this guideline update to
47 evaluate at what cardiovascular risk level antihypertensive drug treatment is cost effective in
48 people without target organ damage, established cardiovascular disease, renal disease or
49 diabetes.

50 The model was a cost–utility analysis with a lifetime horizon, comparing antihypertensive
51 treatment with no antihypertensive treatment in a population with stage 1 hypertension with a
52 base-case age of 60. The intervention and comparator were compared in 4 QRISK2 10-year

1 cardiovascular risk subgroups to assess whether it is cost effective to use antihypertensive
2 drug treatment in each risk group: 5%, 10%, 15% and 20%. Men and women were also
3 compared separately. Additionally, other age groups were also evaluated: ages 40, 50, 70
4 and 75. A Markov model was used where people begin in a 'no cardiovascular event' state,
5 and can transition to 6 non-fatal cardiovascular event health states of stable angina, unstable
6 angina, myocardial infarction, transient ischaemic attack, stroke and heart failure, as well as
7 2 fatal states of cardiovascular and non-cardiovascular death. Repeat events were not
8 modelled. The costs considered included drug treatment and monitoring, adverse events
9 (acute kidney injury [AKI] and falls), and treating cardiovascular events. The model methods
10 are summarised in section 1.6.3, with full methods reported in Appendix 1.

11 The results of the model showed that in the base-case age group (age 60), treatment was
12 cost effective at a 10 year cardiovascular risk threshold of just over 5% for both men and
13 women (5.4% for men and 5.3% for women). The probability of treatment being cost effective
14 at 10% for men and women aged 60 was around 84-86%. Comparison of these thresholds
15 with the minimum QRISK2 levels for men and women aged 60 showed that it would be cost
16 effective to treat all people aged 60 with stage 1 hypertension. The probability of treatment
17 being cost effective at the 5% level was around 50% for both sexes, but uncertainty is likely
18 to be higher in women, as they tend to have lower calculated risk: if a woman aged 60 was at
19 very low risk (that is, close to the QRISK2 minimum risk level of 5.3%), then there would be
20 significant uncertainty as to whether treatment or no treatment was the most cost effective
21 option.

22 Results from the other age subgroups showed that the younger the population, the lower the
23 risk level that it was cost effective to treat above, as younger people live longer and thus
24 have more time to benefit from treatment. Comparing the risk thresholds the model predicted
25 for each age group with the minimum risk levels calculated showed that it was cost effective
26 to treat all ages with stage 1 hypertension except women aged 40 and 50, where the model
27 risk thresholds were higher than the minimum risk levels: risk is very low in younger women.

28 A sensitivity analysis on differential treatment durations was undertaken to take into account
29 that people may become eligible for treatment in the future for other reasons. This involved
30 testing arbitrary time points at which people in the no treatment arm started treatment, in
31 order to imitate subsequent treatment and to see how this would affect results. For the base-
32 case age group (60), the assumptions around differential treatment duration that were tested
33 did not change the results because all risk thresholds identified were similar and were still
34 lower than the minimum QRISK2 values. Testing differential treatment durations and whether
35 that impacted the main conclusions for the other age groups, showed that in men it wasn't
36 cost effective anymore to treat all men aged 40 and 50 if they were likely to develop other
37 reasons for going onto treatment in shorter durations of time 1–10 years. For women, the
38 conclusions did not change when differential treatment durations were tested.

39 The model was very sensitive to a more favourable treatment effect, as treatment became
40 cost effective at the 5% risk level even for those aged 75. Conversely, no treatment benefit
41 would mean antihypertensive treatment is not cost effective. Other sensitivity analyses were
42 only undertaken deterministically for the 60-year-old group. Inputs that changed the results
43 by making treatment cost effective even at 5% risk included smaller drug costs, higher health
44 state costs, nurses undertaking monitoring, not including adverse events, events, having
45 higher annual cardiovascular (CV) risk increases for women, and lower utilities. Various
46 inputs that would bias against treatment (like increasing cost) made treatment less cost
47 effective but hardly ever to the extent that the 10% risk subgroup was not cost effective.

48 The committee's interpretation of the economic model was that it was overall conservative
49 towards treatment, but they had greater confidence that treating at 10% risk was cost
50 effective compared to 5% risk in the base-case age group results. There was also more
51 uncertainty around people younger than 60 because it was shown not to be cost effective to
52 treat all women aged 40 and 50 with stage 1 hypertension, and the conclusions changed for

1 men aged 40 and 50 in the differential treatment durations. Treating at a younger age also
2 subjects people to more years of treatment, and there were also concerns about over-
3 medicalisation of younger people at low risk of subsequent cardiovascular events.
4 Conversely, there were concerns that lifetime risk in a young hypertensive would be relatively
5 high and that delaying treatment might lead to preventable harm. Additionally, stage 1
6 hypertension in a younger age group, for example age 40, is more likely to lead to early
7 onset target organ damage, so a greater proportion will subsequently be eligible for
8 treatment. The observational study included in the guideline review, by Sheppard et al,
9 suggested that low-risk individuals (with an average risk of 8%) are unlikely to benefit from
10 treatment. The committee opinion was that this supported the conclusions of the model in
11 terms of there being a higher level of confidence in a more conservative threshold of 10%,
12 because there is uncertainty about treatment effect in lower risk people. Additionally, a recent
13 sub-study of the SPRINT trial looking at the effect of intensive versus standard treatment in
14 cardiovascular risk subgroups showed that in those with lower risk there was more harm than
15 benefit from treatment, whereas those with higher risks had higher benefits, supporting that
16 there is a higher absolute benefit from treatment to those at higher risk.

17 Clinicians often find it more helpful to explain the benefits of treatment to people in terms of
18 numbers needed to treat (NNT). The 10-year minimum risk levels calculated from the
19 QRISK2 were converted to 5-year risks (as 5-year NNTs are more typical) and combined
20 with the relative treatment effect used in the model to derive NNTs. The committee agreed
21 that these confirmed their previous thinking that the NNTs for antihypertensive treatment in a
22 stage 1 population were favourable.

23 The committee discussed what it would currently do in practice and noted there is variation in
24 how the recommendation from CG127 of treating above a 20% cardiovascular risk threshold
25 has been implemented. Some UK research by Sheppard et al¹³⁷ using CPRD data on people
26 with untreated stage 1 hypertension and average age of 52 years showed that around half
27 were already receiving either antihypertensive treatment alone or antihypertensive treatment
28 alongside lifestyle advice. Given the average age of the population in this study, it was likely
29 that the cardiovascular risk for that population was significantly below the current 20% CVD
30 risk threshold for initiation of drug therapy and likely in the range of 5–15%. Some clinicians
31 who see younger people who might have a low 10 year risk but have sustained stage 1
32 hypertension would offer treatment to those individuals even in the absence of established
33 target organ damage as their lifetime risk is significant. Some risk factors such as family
34 history of hypertension are not included in the QRISK CVD calculator but have a significant
35 disease-associated effect for hypertension and would disproportionately manifest in younger
36 age groups. Furthermore, some clinicians appear to be of the opinion that the threshold to
37 treat hypertension is 10% because that is the threshold recommended in the Lipids guideline
38 for treatment of risk of atherosclerotic disease as the process of atherosclerosis involves
39 both risk factors and they do not differentiate their importance based on therapy effects.
40 Overall, there is significant heterogeneity as to whether an individual is offered treatment
41 (and whether it is implemented). The committee acknowledged the difficulty in its discussion
42 of being able to suggest a single rule about who should and should not be treated and how
43 this would be done on an individualised basis in clinical practice.

44 The committee agreed advice on lifestyle modifications should be offered to all with
45 hypertension and in particular to be the first intervention offered when someone is identified
46 as having stage 1 hypertension. Sheppard et al identified that not everyone that is on
47 treatment has had prior lifestyle advice recorded.

48 Overall, the committee discussed the many different factors that would need to be
49 considered in order to reach a recommendation: (1) the results of the model and the
50 confidence in treatment benefit in different risk levels; (2) the variability in how the current
51 risk threshold recommended is applied; (3) individual patient choice; and (4) the resource
52 impact and population that will potentially be affected by lowering the risk threshold. The
53 committee agreed that an acceptable compromise was to offer treatment above a risk level

1 of 10%, and consider treatment below a risk level of 10% in specific populations. A 10% risk
2 threshold would also be in line with the threshold from CG181; therefore, this would translate
3 into practice more easily if treatment for different cardiovascular disease risk factors had a
4 common threshold.

5 The committee noted how the current age that people are generally started on
6 antihypertensive treatment was around age 60 and had evidence from UK practice that many
7 people are started on antihypertensive treatment at a lower age. This is in keeping with a risk
8 threshold of 10% already being the established default in clinical practice because using the
9 minimum risk values that were used for validation in the model: a man or woman would have
10 10% risk at between the age of 60 and 70. A 'consider' recommendation was made for those
11 with risk under 10% to capture that in younger people, individual preferences and
12 circumstances are likely to have the biggest impact on the treatment decision. A 'consider'
13 recommendation was also made for people aged over 80, who previously did not have a
14 specific recommendation and therefore this was interpreted in practice as they should not be
15 treated. The committee felt there were many factors to consider with regards to starting
16 treatment above the age of 80 such as com-morbidities and again an individualised
17 discussion should be had.

18 These recommendations are likely to have a significant cost impact due to the number of
19 people affected and the predictable increase in monitoring visits and drug treatment that will
20 be involved. The exact extent of the cost impact is uncertain depending on how closely the
21 current threshold for treatment is being followed in practice. See 'other factors the committee
22 took into account' below for some rough information on this. Treating at a lower threshold
23 might also have other benefits aside from reducing cardiovascular events, such as the earlier
24 detection of severe forms of hypertension, as people who are not on drug treatment are less
25 likely to return for regular monitoring.

1.9.36 Other factors the committee took into account

27 The committee noted that family origin is one of the factors taken into account in
28 cardiovascular risk assessments such as QRISK, which increases the estimated CV risk
29 within this population. Therefore, all people irrespective of family origin are adequately
30 addressed by these recommendations.

31 In terms of the population impact of the recommendations made, information from the Health
32 Survey for England 2006 (the latest version that undertook a cardiovascular survey) on the
33 proportion of people with untreated stage 1 hypertension aged 35–74, combined with 2017
34 population estimated for England, show this is around 2.2 million men and 1.7 million
35 women. The proportion of people with CV risk level between 10% and 20% is around 20% of
36 men and 16% of women.⁴³ These risk proportions are not exclusively in people with stage 1
37 hypertension, so these are very crude estimates. Combining those 2 pieces of information
38 shows that around 450,000 men and 270,000 women would fall into the category of stage 1
39 hypertension with CV risk of between 10% and 20%. It was discussed how these are likely to
40 be overestimates as practice has changed since the health survey for England and more
41 people are likely to be treated now (for example, around 50% of patients with stage 1
42 hypertension are below 20% risk based on Sheppard 2018). Even though the
43 antihypertensive drugs are relatively low cost, given the number of additional people that
44 would be treated, these recommendations will have a significant resource impact.

1 References

- 2 1. Adamsson Eryd S, Gudbjornsdottir S, Manhem K, Rosengren A, Svensson AM,
3 Miftaraj M et al. Blood pressure and complications in individuals with type 2 diabetes
4 and no previous cardiovascular disease: National population based cohort study.
5 *BMJ*. 2016; 354:i4070
- 6 2. Akanabe H, Ishiguro M, Yagi Y, Ohshima S, Ohmae M, Mori H et al. Effect of
7 diltiazem hydrochloride in essential hypertension. *International Journal of Clinical*
8 *Pharmacology, Therapy, and Toxicology*. 1985; 23(2):63-9
- 9 3. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive
10 patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-
11 lowering treatment to prevent heart attack trial (ALLHAT). *JAMA*. 2000; 283(15):1967-
12 1975
- 13 4. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC et al.
14 The design and rationale of a multicenter clinical trial comparing two strategies for
15 control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial
16 (SPRINT). *Clinical Trials*. 2014; 11(5):532-546
- 17 5. Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN. Effect of
18 baseline and changes in systolic blood pressure over time on the effectiveness of
19 valsartan in the Valsartan Heart Failure Trial. *Circulation: Heart Failure*. 2008;
20 1(1):34-42
- 21 6. Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT et al.
22 Influence of blood pressure on the effectiveness of a fixed-dose combination of
23 isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.
24 *Journal of the American College of Cardiology*. 2007; 49(1):32-9
- 25 7. Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A et al. Predictors of
26 cardiovascular events in patients with type 2 diabetic nephropathy and hypertension:
27 A case for albuminuria. *Kidney International*. 2004; 66(Suppl 92):S50-S55
- 28 8. Anderson RJ, Bahn GD, Moritz TE, Kaufman D, Abaira C, Duckworth W. Blood
29 pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial.
30 *Diabetes Care*. 2011; 34(1):34-38
- 31 9. Anonymous. Treating blood pressure between 140/90 and 160/95 mmHg: No proven
32 benefit. *Prescrire International*. 2014; 23(148):106
- 33 10. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S et al. Lower
34 target blood pressures are safe and effective for the prevention of recurrent stroke:
35 The PROGRESS trial. *Journal of Hypertension*. 2006; 24(6):1201-8
- 36 11. Arima H, Tanizaki Y, Yonemoto K, Doi Y, Ninomiya T, Hata J et al. Impact of blood
37 pressure levels on different types of stroke: The Hisayama study. *Journal of*
38 *Hypertension*. 2009; 27(12):2437-43
- 39 12. Arnold JMO, Yusuf S, Young J, Mathew J, Johnstone D, Avezum A et al. Prevention
40 of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE)
41 study. *Circulation*. 2003; 107(9):1284-1290
- 42 13. Asayama K. Observational study and participant-level meta-analysis on
43 antihypertensive drug treatment-related cardiovascular risk. *Hypertension Research*.
44 2017; 40(10):856-860

- 1 14. Asayama K, Ohkubo T, Hanazawa T, Watabe D, Hosaka M, Satoh M et al. Does
2 antihypertensive drug class affect day-to-day variability of self-measured home blood
3 pressure? The HOMED-BP Study. *Journal of the American Heart Association*. 2016;
4 5(3):e002995
- 5 15. Asayama K, Ohkubo T, Metoki H, Obara T, Inoue R, Kikuya M et al. Cardiovascular
6 outcomes in the first trial of antihypertensive therapy guided by self-measured home
7 blood pressure. *Hypertension Research*. 2012; 35(11):1102-1110
- 8 16. Asayama K, Ohkubo T, Satoh A, Tanaka S, Higashiyama A, Murakami Y et al.
9 Cardiovascular risk and blood pressure lowering treatment among elderly individuals:
10 Evidence for cardiovascular prevention from observational cohorts in Japan. *Journal*
11 *of Hypertension*. 2018; 36(2):410-418
- 12 17. Asayama K, Ohkubo T, Yoshida S, Suzuki K, Metoki H, Harada A et al. Stroke risk
13 and antihypertensive drug treatment in the general population: The Japan
14 arteriosclerosis longitudinal study. *Journal of Hypertension*. 2009; 27(2):357-64
- 15 18. Asayama K, Satoh M, Murakami Y, Ohkubo T, Nagasawa SY, Tsuji I et al.
16 Cardiovascular risk with and without antihypertensive drug treatment in the Japanese
17 general population: Participant-level meta-analysis. *Hypertension*. 2014; 63(6):1189-
18 97
- 19 19. Asayama K, Thijs L, Brguljan-Hitij J, Niiranen TJ, Hozawa A, Boggia J et al. Risk
20 stratification by self-measured home blood pressure across categories of
21 conventional blood pressure: a participant-level meta-analysis. *PLoS Medicine*. 2014;
22 11(1):e1001591
- 23 20. Athanasakis K, Souliotis K, Tountas Y, Kyriopoulos J, Hatzakis A. A cost-utility
24 analysis of hypertension treatment in Greece: Assessing the impact of age, sex and
25 smoking status, on outcomes. *Journal of Hypertension*. 2012; 30(1):227-234
- 26 21. Aydogan U, Doganer YC, Atik ADLDAL, Rohrer JE, Engin Gok D, Cirpan E et al.
27 Blood pressure control in patients with hypertension: A retrospective cohort study.
28 *Journal of Evaluation in Clinical Practice*. 2015; 21(2):313-9
- 29 22. Baker S, Priest P, Jackson R. Using thresholds based on risk of cardiovascular
30 disease to target treatment for hypertension: Modelling events averted and number
31 treated. *BMJ*. 2000; 320(7236):680-685
- 32 23. Banach M, Bromfield S, Howard G, Howard VJ, Zanchetti A, Aronow WS et al.
33 Association of systolic blood pressure levels with cardiovascular events and all-cause
34 mortality among older adults taking antihypertensive medication. *International Journal*
35 *of Cardiology*. 2014; 176(1):219-226
- 36 24. Barengo NC, Hu G, Kastarinen M, Antikainen R, Tuomilehto J. The effects of
37 awareness, treatment and control of hypertension on future stroke incidence in a
38 community-based population study in Finland. *Journal of Hypertension*. 2009;
39 27(7):1459-65
- 40 25. Beckett N, Peters R, Leonetti G, Duggan J, Fagard R, Thijs L et al. Subgroup and
41 per-protocol analyses from the hypertension in the very elderly trial. *Journal of*
42 *Hypertension*. 2014; 32(7):1478-87; discussion 1487
- 43 26. Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA et al. Blood-
44 pressure targets in patients with recent lacunar stroke: The SPS3 randomised trial.
45 *The Lancet*. 2013; 382(9891):507-15

- 1 27. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L et al. Pulse pressure not
2 mean pressure determines cardiovascular risk in older hypertensive patients.
3 Archives of Internal Medicine. 2000; 160(8):1085-9
- 4 28. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB et al. Principal
5 results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points
6 (CONVINCE) trial. JAMA. 2003; 289(16):2073-2082
- 7 29. Blood Pressure Lowering Treatment Trialists Collaboration, Turnbull F, Neal B,
8 Ninomiya T, Algert C, Arima H et al. Effects of different regimens to lower blood
9 pressure on major cardiovascular events in older and younger adults: Meta-analysis
10 of randomised trials. BMJ. 2008; 336:7653
- 11 30. Bohm M, Robertson M, Borer J, Ford I, Komajda M, Mahfoud F et al. Effect of visit-to-
12 visit variation of heart rate and systolic blood pressure on outcomes in chronic
13 systolic heart failure: Results from the systolic heart failure treatment with the if
14 inhibitor ivabradine trial (SHIFT) trial. Journal of the American Heart Association.
15 2016; 5:e002160
- 16 31. Borghi C, Dormi A, D'Addato S, Gaddi A, Ambrosioni E. Trends in blood pressure
17 control and antihypertensive treatment in clinical practice: The Brisighella Heart
18 Study. Journal of Hypertension. 2004; 22(9):1707-1716
- 19 32. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP. J-shaped relationship
20 between blood pressure and mortality in hypertensive patients: New insights from a
21 meta-analysis of individual-patient data. Annals of Internal Medicine. 2002;
22 136(6):438-48
- 23 33. Brimble KS. Targeting blood pressure in people with diabetes mellitus. Polskie
24 Archiwum Medycyny Wewnetrznej. 2016; 126(6):411-8
- 25 34. Brown MJ, Palmer CR, Castaigne A, Leeuw PW, Mancia G, Rosenthal T et al.
26 Morbidity and mortality in patients randomised to double-blind treatment with a long-
27 acting calcium-channel blocker or diuretic in the International Nifedipine GITS study:
28 intervention as a Goal in Hypertension Treatment (INSIGHT). The Lancet. 2000;
29 356(9227):366-372
- 30 35. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood
31 pressure levels in patients with diabetes mellitus: Systematic review and meta-
32 analyses. BMJ. 2016; 352:i717
- 33 36. Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and
34 cardiovascular disease across blood pressure levels: A systematic review and meta-
35 analysis. JAMA Internal Medicine. 2018; 178(1):28-36
- 36 37. Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F et al.
37 Hypertension in the Very Elderly Trial (HYVET): Protocol for the main trial. Drugs and
38 Aging. 2001; 18(3):151-164
- 39 38. Bulpitt CJ, Beevers DG, Butler A, Coles EC, Fletcher AE, Hunt D et al. Treated blood
40 pressure, rather than pretreatment, predicts survival in hypertensive patients. A report
41 from the DHSS Hypertension Care Computing Project (DHCCP). Journal of
42 Hypertension. 1988; 6(8):627-32
- 43 39. Bundy JD, Li C, He J. Impact of intensive systolic blood pressure treatment on
44 cardiovascular disease and mortality in the US population. Circulation. 2017;
45 135(Suppl. 1):180

- 1 40. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT et al. Systolic blood pressure
2 reduction and risk of cardiovascular disease and mortality: A systematic review and
3 network meta-analysis. *JAMA Cardiology*. 2017; 2(7):775-781
- 4 41. Butler J, Kalogeropoulos AP, Georgiopoulou VV, Bibbins-Domingo K, Najjar SS,
5 Sutton-Tyrrell KC et al. Systolic blood pressure and incident heart failure in the
6 elderly. The Cardiovascular Health Study and the Health, Ageing and Body
7 Composition Study. *Heart*. 2011; 97(16):1304-11
- 8 42. Carlsson AC, Theobald H, Hellenius ML, Wandell PE. Cardiovascular and total
9 mortality in men and women with different blood pressure levels: A 26-year follow-up.
10 *Blood Pressure*. 2009; 18(3):105-10
- 11 43. Collins GS, Altman DG. An independent external validation and evaluation of QRISK
12 cardiovascular risk prediction: a prospective open cohort study. *BMJ*. 2009;
13 339:b2584
- 14 44. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP et al. The
15 effects of blood pressure reduction and of different blood pressure-lowering regimens
16 on major cardiovascular events according to baseline blood pressure: meta-analysis
17 of randomized trials. *Journal of Hypertension*. 2011; 29(1):4-16
- 18 45. Deckers JW, Goedhart DM, Boersma E, Briggs A, Bertrand M, Ferrari R et al.
19 Treatment benefit by perindopril in patients with stable coronary artery disease at
20 different levels of risk. *European Heart Journal*. 2006; 27(7):796-801
- 21 46. Derosa G, Bonaventura A, Romano D, Bianchi L, Fogari E, D'Angelo A et al. Effects
22 of enalapril/lercanidipine combination on some emerging biomarkers in
23 cardiovascular risk stratification in hypertensive patients. *Journal of Clinical Pharmacy
24 and Therapeutics*. 2014; 39(3):277-85
- 25 47. Derosa G, Bonaventura A, Romano D, Bianchi L, Fogari E, D'Angelo A et al.
26 Enalapril/lercanidipine combination on markers of cardiovascular risk: A randomized
27 study. *Journal of the American Society of Hypertension*. 2014; 8(6):422-8
- 28 48. Dregan A, Ravindrarajah R, Hazra N, Hamada S, Jackson SHD, Gulliford MC.
29 Longitudinal trends in hypertension management and mortality among octogenarians:
30 Prospective cohort study. *Hypertension*. 2016; 68(1):97-105
- 31 49. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure
32 lowering in type 2 diabetes: A systematic review and meta-analysis. *JAMA*. 2015;
33 313(6):603-15
- 34 50. Estacio RO, Coll JR, Tran ZV, Schrier RW. Effect of intensive blood pressure control
35 with valsartan on urinary albumin excretion in normotensive patients with type 2
36 diabetes. *American Journal of Hypertension*. 2006; 19(12):1241-8
- 37 51. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J et al. Blood
38 pressure lowering for prevention of cardiovascular disease and death: A systematic
39 review and meta-analysis. *The Lancet*. 2016; 387(10022):957-967
- 40 52. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat,
41 masked and sustained hypertension versus true normotension: A meta-analysis.
42 *Journal of Hypertension*. 2007; 25(11):2193-2198
- 43 53. Fagard RH, Staessen JA. Treatment of isolated systolic hypertension in the elderly:
44 The Syst-Eur trial. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
45 *Clinical and Experimental Hypertension*. 1999; 21(5-6):491-497

- 1 54. Feldstein CA. Lowering blood pressure to prevent stroke recurrence: A systematic
2 review of long-term randomized trials. *Journal of the American Society of*
3 *Hypertension*. 2014; 8(7):503-13
- 4 55. Ferket BS, Hunink MG, Khanji M, Agarwal I, Fleischmann KE, Petersen SE. Cost-
5 effectiveness of the polypill versus risk assessment for prevention of cardiovascular
6 disease. *Heart*. 2017; 103(7):483-491
- 7 56. Ferrucci L, Furberg CD, Penninx BW, DiBari M, Williamson JD, Guralnik JM et al.
8 Treatment of isolated systolic hypertension is most effective in older patients with
9 high-risk profile. *Circulation*. 2001; 104(16):1923-1926
- 10 57. Filippi A, Casula M, Tragni E, Brignoli O, Cricelli C, Poli A et al. Blood pressure and
11 antihypertensive therapy according to the global cardiovascular risk level in Italy: The
12 CHECK Study. *European Journal of Cardiovascular Prevention and Rehabilitation*.
13 2010; 17(5):562-8
- 14 58. Freitag MH, Vasani RS. What is normal blood pressure? *Current Opinion in*
15 *Nephrology and Hypertension*. 2003; 12(3):285-92
- 16 59. Frontoni S, Solini A, Fioretto P, Natali A, Zuccala A, Cosentino F et al. The ideal
17 blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral
18 viewpoint. *Nutrition, Metabolism, and Cardiovascular Diseases*. 2014; 24(6):577-84
- 19 60. Fuchs FD, Fuchs SC, Moreira LB, Gus M, Nobrega AC, Poli-de-Figueiredo CE et al.
20 Prevention of hypertension in patients with pre-hypertension: Protocol for the
21 PREVER-prevention trial. *Trials*. 2011; 12:65
- 22 61. Fuchs SC, Poli-de-Figueiredo CE, Figueiredo Neto JA, Scala LC, Whelton PK,
23 Mosele F et al. Effectiveness of chlorthalidone plus amiloride for the prevention of
24 hypertension: The PREVER-prevention randomized clinical trial. *Journal of the*
25 *American Heart Association*. 2016; 5(12):e004248
- 26 62. Garrison SR, Kolber MR, Korownyk CS, McCracken RK, Heran BS, Allan GM. Blood
27 pressure targets for hypertension in older adults. *Cochrane Database of Systematic*
28 *Reviews* 2017, Issue 8. Art. No.: CD011575. DOI:
29 <https://dx.doi.org/10.1002/14651858.CD011575.pub2>
- 30 63. Geraci TS, Geraci SA. What ALLHAT tells us about treating high-risk patients with
31 hypertension and hyperlipidemia. *Journal of Cardiovascular Nursing*. 2003;
32 18(5):389-395
- 33 64. Grassi G, Quarti-Trevano F, Casati A, Dell'Oro R. Threshold and target for blood
34 pressure lowering in the elderly. *Current Atherosclerosis Reports*. 2016; 18(12):70
- 35 65. Gueyffier F, Boissel JP, Pocock S, Boutitie F, Coope J, Cutler J et al. Identification of
36 risk factors in hypertensive patients: Contribution of randomized controlled trials
37 through an individual patient database. *Circulation*. 1999; 100(18):e88-94
- 38 66. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J et al. Effect of
39 antihypertensive drug treatment on cardiovascular outcomes in women and men. A
40 meta-analysis of individual patient data from randomized, controlled trials. *Annals of*
41 *Internal Medicine*. 1997; 126(10):761-7
- 42 67. Hansen TW, Staessen JA, Zhang H, Torp-Pedersen C, Rasmussen S, Thijs L et al.
43 Cardiovascular outcome in relation to progression to hypertension in the Copenhagen
44 MONICA cohort. *American Journal of Hypertension*. 2007; 20(5):483-491
- 45 68. Hara A, Thijs L, Asayama K, Jacobs L, Wang JG, Staessen JA. Randomised double-
46 blind comparison of placebo and active drugs for effects on risks associated with

- 1 blood pressure variability in the Systolic Hypertension in Europe trial. *PloS One*.
2 2014; 9(8):e103169
- 3 69. Ho CLB, Breslin M, Doust J, Reid CM, Nelson MR. Effectiveness of blood pressure-
4 lowering drug treatment by levels of absolute risk: Post hoc analysis of the Australian
5 National Blood Pressure Study. *BMJ Open*. 2018; 8:e017723
- 6 70. Hong Z, Wu T, Zhou S, Huang B, Wang J, Jin D et al. Effects of anti-hypertensive
7 treatment on major cardiovascular events in populations within prehypertensive
8 levels: A systematic review and meta-analysis. *Journal of Human Hypertension*.
9 2018; 32(2):94-104
- 10 71. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA et al.
11 Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in
12 diabetes: The SANDS randomized trial. *JAMA*. 2008; 299(14):1678-1689
- 13 72. Huse DM, Roht LH, Hartz SC. Selective use of calcium channel blockers to treat
14 high-risk hypertensive patients. *Pharmacoepidemiology and Drug Safety*. 2000;
15 9(1):1-9
- 16 73. In der Schmitzen J, Wegscheider K, Abholz HH, Mortsiefer A. Risk-adjusted versus
17 overall blood pressure control rate for identifying the need for intensified
18 cardiovascular risk reduction: lessons from a cross-sectional study. *European Journal*
19 *of Preventive Cardiology*. 2013; 20(6):972-979
- 20 74. Isezuo AS, Njoku CH. Blood pressure control among hypertensives managed in a
21 specialised health care setting in Nigeria. *African Journal of Medicine and Medical*
22 *Sciences*. 2003; 32(1):65-70
- 23 75. Ishikawa S, Kario K, Kayaba K, Gotoh T, Nago N, Nakamura Y et al. Continued high
24 risk of stroke in treated hypertensives in a general population: The Jichi Medical
25 School Cohort study. *Hypertension Research*. 2008; 31(6):1125-33
- 26 76. Izzo JL, Jr. Benefits of antihypertensive drugs when blood pressure is below 140/90
27 mmHg. *Polskie Archiwum Medycyny Wewnetrznej*. 2011; 121(9):303-9
- 28 77. Jacobs L, Efremov L, Ferreira JP, Thijs L, Yang WY, Zhang ZY et al. Risk for incident
29 heart failure: A subject-level meta-analysis from the heart "OMics" in AGEing
30 (HOMAGE) STUDY. *Journal of the American Heart Association*. 2017; 6(5):1-10
- 31 78. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic
32 blood pressure in elderly hypertensive patients (JATOS). *Hypertension Research*.
33 2008; 31(12):2115-27
- 34 79. Johnson G, Carson P, Francis GS, Cohn JN. Influence of prerandomization
35 (baseline) variables on mortality and on the reduction of mortality by enalapril.
36 Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT
37 II). V-HeFT VA Cooperative Studies Group. *Circulation*. 1993; 87(Suppl):VI32-9
- 38 80. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N et al. Feasibility
39 of treating prehypertension with an angiotensin-receptor blocker. *New England*
40 *Journal of Medicine*. 2006; 354(16):1685-1697
- 41 81. Kagiya S, Fukuhara M, Ansai T, Matsumura K, Soh I, Takata Y et al. Association
42 between blood pressure and mortality in 80-year-old subjects from a population-
43 based prospective study in Japan. *Hypertension Research*. 2008; 31(2):265-70
- 44 82. Kalkman DN, Brouwer TF, Vehmeijer JT, Berger WR, Knops RE, de Winter RJ et al.
45 J curve in patients randomly assigned to different systolic blood pressure targets: An

- 1 experimental approach to an observational paradigm. *Circulation*. 2017;
2 136(23):2220-2229
- 3 83. Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD. Risk
4 scoring for the primary prevention of cardiovascular disease. *Cochrane Database of*
5 *Systematic Reviews* 2017, Issue 3. Art. No.: CD006887. DOI:
6 <http://dx.doi.org/10.1002/14651858.CD006887.pub4>.
- 7 84. Kengne AP, Czernichow S, Huxley R, Grobbee D, Woodward M, Neal B et al. Blood
8 pressure variables and cardiovascular risk: New findings from ADVANCE.
9 *Hypertension*. 2009; 54(2):399-404
- 10 85. Kim JH, Zamorano J, Erdine S, Pavia A, Al-Khadra A, Sutradhar S et al. Reduction in
11 cardiovascular risk using proactive multifactorial intervention versus usual care in
12 younger (< 65 years) and older (>= 65 years) patients in the CRUCIAL trial. *Current*
13 *Medical Research and Opinion*. 2013; 29(5):453-63
- 14 86. Kokubo Y, Kamide K, Okamura T, Watanabe M, Higashiyama A, Kawanishi K et al.
15 Impact of high-normal blood pressure on the risk of cardiovascular disease in a
16 Japanese urban cohort: The Suita study. *Hypertension*. 2008; 52(4):652-9
- 17 87. Ku E, Scherzer R, Odden MC, Shlipak M, White CL, Field TS et al. Patterns of blood
18 pressure response during intensive BP lowering and clinical events: results from the
19 secondary prevention of small subcortical strokes trial. *Blood Pressure*. 2018;
20 27(2):73-81
- 21 88. Kypridemos C, Collins B, McHale P, Bromley H, Parvulescu P, Capewell S et al.
22 Future cost-effectiveness and equity of the NHS Health Check cardiovascular
23 disease prevention programme: Microsimulation modelling using data from Liverpool,
24 UK. *PLoS Medicine / Public Library of Science*. 2018; 15(5):e1002573
- 25 89. Lachouri M, Gourlet V, D'Athis P, Tzourio C, Quantin C. Changes in blood pressure in
26 a large cohort of elderly individuals: Study 3C. *Archives of Cardiovascular Diseases*.
27 2009; 102(2):127-34
- 28 90. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention
29 of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of
30 expectations from prospective epidemiological studies. *BMJ*. 2009; 338:b1665
- 31 91. Le HH, Subtil F, Cerou M, Marchant I, Al-Gobari M, Fall M et al. A sudden death risk
32 score specifically for hypertension: Based on 25 648 individual patient data from six
33 randomized controlled trials. *Journal of Hypertension*. 2017; 35(11):2178-2184
- 34 92. Lee M, Saver JL, Hong KS, Hao Q, Ovbiagele B. Does achieving an intensive versus
35 usual blood pressure level prevent stroke? *Annals of Neurology*. 2012; 71(1):133-40
- 36 93. Li C, Engstrom G, Hedblad B, Berglund G, Janzon L. Blood pressure control and risk
37 of stroke: a population-based prospective cohort study. *Stroke*. 2005; 36(4):725-30
- 38 94. Li W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Hu G. Blood pressure and all-
39 cause mortality among patients with type 2 diabetes. *International Journal of*
40 *Cardiology*. 2016; 206:116-21
- 41 95. Li Y, Wei FF, Wang S, Cheng YB, Wang JG. Cardiovascular risks associated with
42 diastolic blood pressure and isolated diastolic hypertension. *Current Hypertension*
43 *Reports*. 2014; 16(11):489
- 44 96. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The Study on
45 Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized
46 double-blind intervention trial. *Journal of Hypertension*. 2003; 21(5):875-86

- 1 97. Liu K, Colangelo LA, Daviglius ML, Goff DC, Pletcher M, Schreiner PJ et al. Can
2 antihypertensive treatment restore the risk of cardiovascular disease to ideal levels?:
3 The coronary artery risk development in young adults (CARDIA) study and the multi-
4 ethnic study of atherosclerosis (MESA). *Journal of the American Heart Association*.
5 2015; 4:e002275
- 6 98. Liu L, Wang Z, Gong L, Zhang Y, Thijs L, Staessen JA et al. Blood pressure reduction
7 for the secondary prevention of stroke: A Chinese trial and a systematic review of the
8 literature. *Hypertension Research*. 2009; 32(11):1032-40
- 9 99. Lonn E, Bosch J, Pogue J, Avezum A, Chazova I, Dans A et al. Novel approaches in
10 primary cardiovascular disease prevention: The HOPE-3 trial rationale, design, and
11 participants' baseline characteristics. *Canadian Journal of Cardiology*. 2016;
12 32(3):311-8
- 13 100. Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P et al. Blood-pressure
14 lowering in intermediate-risk persons without cardiovascular disease. *New England*
15 *Journal of Medicine*. 2016; 374(21):2009-2020
- 16 101. Lopez-Paz JE, Hermida A, Pena M, Calvo G, Romero L, Sierra C et al. Amlodipine
17 and atorvastatin combination in the treatment of the high-risk hypertensive patient.
18 *Journal of Clinical Hypertension*. 2010; 12(Suppl 1):A38
- 19 102. Luders S, Schrader J, Berger J, Unger T, Zidek W, Bohm M et al. The PHARAO
20 study: Prevention of hypertension with the angiotensin-converting enzyme inhibitor
21 ramipril in patients with high-normal blood pressure: A prospective, randomized,
22 controlled prevention trial of the German Hypertension League. *Journal of*
23 *Hypertension*. 2008; 26(7):1487-96
- 24 103. Lund Haheim L, Holme I, Hjermann I, Leren P. Risk of fatal stroke according to blood
25 pressure level: An 18-year follow-up of the Oslo Study. *Journal of Hypertension*.
26 1995; 13(8):909-913
- 27 104. Ma L, Wang W, Zhao Y, Zhang Y, Deng Q, Liu M et al. Combination of amlodipine
28 plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: A 96-
29 week efficacy and safety study. *American Journal of Cardiovascular Drugs*. 2012;
30 12(2):137-142
- 31 105. MacMahon S, Neal B, Cutler J, Anderson C, Chalmers J, Ohkubo T et al.
32 Randomised trial of a perindopril-based blood-pressure-lowering regimen among
33 6105 individuals with previous stroke or transient ischaemic attack. *The Lancet*. 2001;
34 358(9287):1033-1041
- 35 106. Mancia G, Kjeldsen SE, Zappe DH, Holzhauser B, Hua TA, Zanchetti A et al.
36 Cardiovascular outcomes at different on-treatment blood pressures in the
37 hypertensive patients of the VALUE trial. *European Heart Journal*. 2016; 37(12):955-
38 964
- 39 107. Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC et al.
40 Outcomes of combined cardiovascular risk factor management strategies in type 2
41 diabetes: The accord randomized trial. *Diabetes Care*. 2014; 37(6):1721-1728
- 42 108. Mariampillai JE, Eskas PA, Heimark S, Kjeldsen SE, Narkiewicz K, Mancia G. A case
43 for less intensive blood pressure control: It matters to achieve target blood pressure
44 early and sustained below 140/90mmHg. *Progress in Cardiovascular Diseases*. 2016;
45 59(3):209-218
- 46 109. Mehlum MH, Liestol K, Kjeldsen SE, Julius S, Hua TA, Rothwell PM et al. Blood
47 pressure variability and risk of cardiovascular events and death in patients with

- 1 hypertension and different baseline risks. *European Heart Journal*. 2018;
2 39(24):2243-2251
- 3 110. Meredith PA, Lloyd SM, Ford I, Elliott HL. Importance of sustained and "tight" blood
4 pressure control in patients with high cardiovascular risk. *Blood Pressure*. 2016;
5 25(2):74-82
- 6 111. Meredith PA, Ostergren J, Anand I, Puu M, Solomon SD, Michelson EL et al. Clinical
7 outcomes according to baseline blood pressure in patients with a low ejection fraction
8 in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality
9 and Morbidity) Program. *Journal of the American College of Cardiology*. 2008;
10 52(24):2000-7
- 11 112. Moraes AAI, Baena CP, Muka T, Bano A, Buitrago-Lopez A, Zazula A et al. Achieved
12 systolic blood pressure in older people: A systematic review and meta-analysis. *BMC*
13 *Geriatrics*. 2017; 17:279
- 14 113. Muntner P, Whelton PK. Using predicted cardiovascular disease risk in conjunction
15 with blood pressure to guide antihypertensive medication treatment. *Journal of the*
16 *American College of Cardiology*. 2017; 69(19):2446-2456
- 17 114. Myers MG, Kaczorowski J, Dolovich L, Tu K, Paterson JM. Cardiovascular risk in
18 hypertension in relation to achieved blood pressure using automated office blood
19 pressure measurement. *Hypertension*. 2016; 68(4):866-872
- 20 115. Nakamura Y, Yamamoto T, Okamura T, Kadowaki T, Hayakawa T, Kita Y et al.
21 Combined cardiovascular risk factors and outcome: NIPPON DATA80, 1980-1994.
22 *Circulation Journal*. 2006; 70(8):960-4
- 23 116. National Clinical Guideline Centre. Lipid modification: cardiovascular risk assessment
24 and the modification of blood lipids for the primary and secondary prevention of
25 cardiovascular disease. NICE clinical guideline 181. London. National Clinical
26 Guideline Centre, 2014. Available from: <http://guidance.nice.org.uk/CG181>
- 27 117. National Institute for Health and Care Excellence. Developing NICE guidelines: the
28 manual. London. National Institute for Health and Care Excellence, 2014. Available
29 from:
30 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
- 31 118. Nelson MR, Chowdhury EK, Doust J, Reid CM, Wing LMH. Ten-year legacy effects of
32 baseline blood pressure 'treatment naivety' in the Second Australian National Blood
33 Pressure study. *Journal of Hypertension*. 2015; 33(11):2331-2337
- 34 119. Ninomiya T, Perkovic V, Gallagher M, Jardine M, Cass A, Arima H et al. Lower blood
35 pressure and risk of recurrent stroke in patients with chronic kidney disease:
36 PROGRESS trial. *Kidney International*. 2008; 73(8):963-70
- 37 120. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D et al. Effect of
38 antihypertensive agents on cardiovascular events in patients with coronary disease
39 and normal blood pressure: The CAMELOT study: A randomized controlled trial.
40 *JAMA*. 2004; 292(18):2217-25
- 41 121. Ntaios G, Lambrou D, Michel P. Blood pressure change and outcome in acute
42 ischemic stroke: The impact of baseline values, previous hypertensive disease and
43 previous antihypertensive treatment. *Journal of Hypertension*. 2011; 29(8):1583-9
- 44 122. Obara F, Saitoh S, Takagi S, Shimamoto K. Influence of hypertension on the
45 incidence of cardiovascular disease in two rural communities in Japan: The Tanno-
46 Sobetsu [corrected] study. *Hypertension Research*. 2007; 30(8):677-82

- 1 123. Ogihara T, Nakao K, Fukui T, Fukiyama K, Fujimoto A, Ueshima K et al. The optimal
2 target blood pressure for antihypertensive treatment in Japanese elderly patients with
3 high-risk hypertension: A subanalysis of the Candesartan Antihypertensive Survival
4 Evaluation in Japan (CASE-J) trial. *Hypertension Research*. 2008; 31(8):1595-1601
- 5 124. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K et al. Target
6 blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan
7 in elderly isolated systolic hypertension study. *Hypertension*. 2010; 56(2):196-202
- 8 125. Ohkuma T, Woodward M, Jun M, Muntner P, Hata J, Colagiuri S et al. Prognostic
9 value of variability in systolic blood pressure related to vascular events and premature
10 death in type 2 diabetes mellitus: The advance-on study. *Hypertension*. 2017;
11 70(2):461-468
- 12 126. Papademetriou V, Zaheer M, Doumas M, Lovato L, Applegate WB, Tsioufis C et al.
13 Cardiovascular outcomes in action to control cardiovascular risk in diabetes: Impact
14 of blood pressure level and presence of kidney disease. *American Journal of
15 Nephrology*. 2016; 43(4):271-80
- 16 127. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L et al. Effects of a
17 fixed combination of perindopril and indapamide on macrovascular and microvascular
18 outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A
19 randomised controlled trial. *The Lancet*. 2007; 370(9590):829-40
- 20 128. Patel KK, Arnold SV, Chan PS, Tang Y, Pokharel Y, Jones PG et al. Personalizing
21 the intensity of blood pressure control: Modeling the heterogeneity of risks and
22 benefits from SPRINT (Systolic Blood Pressure Intervention Trial). *Circulation:
23 Cardiovascular Quality and Outcomes*. 2017; 10(4)
- 24 129. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for
25 predicting risk of death from cardiovascular disease in adults with raised blood
26 pressure, based on individual patient data from randomised controlled trials. *BMJ*.
27 2001; 323(7304):75-81
- 28 130. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, Leeuw PW et al. Systolic
29 blood pressure variability as a risk factor for stroke and cardiovascular mortality in the
30 elderly hypertensive population. *Journal of Hypertension*. 2003; 21(12):2251-2257
- 31 131. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J et al. Safety and
32 efficacy of low blood pressures among patients with diabetes: Subgroup analyses
33 from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril
34 Global Endpoint Trial). *Journal of the American College of Cardiology*. 2012;
35 59(1):74-83
- 36 132. Remme WJ, Deckers JW, Fox KM, Ferrari R, Bertrand M, Simoons ML. Secondary
37 prevention of coronary disease with ACE inhibition-does blood pressure reduction
38 with perindopril explain the benefits in EUROPA? *Cardiovascular Drugs and Therapy*.
39 2009; 23(2):161-70
- 40 133. Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA et al. Influence
41 of pretreatment systolic blood pressure on the effect of carvedilol in patients with
42 severe chronic heart failure: The Carvedilol Prospective Randomized Cumulative
43 Survival (COPERNICUS) study. *Journal of the American College of Cardiology*. 2004;
44 43(8):1423-9
- 45 134. Ruggenenti P, Porrini E, Motterlini N, Perna A, Ilieva AP, Iliev IP et al. Measurable
46 urinary albumin predicts cardiovascular risk among normoalbuminuric patients with
47 type 2 diabetes. *Journal of the American Society of Nephrology*. 2012; 23(10):1717-
48 1724

- 1 135. Shapiro BP, Ambrosius WT, Blackshear JL, Cushman WC, Whelton PK, Oparil S et al. Impact of intensive versus standard blood pressure management by tertiles of
2 al. Impact of intensive versus standard blood pressure management by tertiles of
3 blood pressure in SPRINT (Systolic Blood Pressure Intervention Trial). *Hypertension*.
4 2018; 71(6):1064-1074
- 5 136. Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Hobbs FDR et al. Benefits
6 and harms of antihypertensive treatment in low-risk patients with mild hypertension.
7 *JAMA Internal Medicine*. 2018:E1-E9
- 8 137. Sheppard JP, Stevens S, Stevens RJ, Mant J, Martin U, Hobbs FDR et al.
9 Association of guideline and policy changes with incidence of lifestyle advice and
10 treatment for uncomplicated mild hypertension in primary care: a longitudinal cohort
11 study in the Clinical Practice Research Datalink. *BMJ Open*. 2018; 8(9):e021827
- 12 138. Shiraishi J, Sawada T, Koide M, Yamada H, Matsubara H, Kyoto Heart Study Group.
13 Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive
14 patients with coronary artery disease (from the Kyoto Heart Study). *American Journal of*
15 *Cardiology*. 2012; 109(9):1308-14
- 16 139. Singh V. Review: ACE-Is or ARBs reduce adverse CV outcomes regardless of
17 baseline systolic blood pressure. *Annals of Internal Medicine*. 2012; 157(2):JC2-8
- 18 140. Sipahi I, Swaminathan A, Natesan V, Debanne SM, Simon DI, Fang JC. Effect of
19 antihypertensive therapy on incident stroke in cohorts with prehypertensive blood
20 pressure levels: A meta-analysis of randomized controlled trials. *Stroke*. 2012;
21 43(2):432-40
- 22 141. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R et al. Prognostic value
23 of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone
24 and in combination with Ramipril Global Endpoint Trial study. *Journal of*
25 *Hypertension*. 2009; 27(7):1360-9
- 26 142. Stevanovic J, O'Prinsen AC, Verheggen BG, Schuiling-Veninga N, Postma MJ,
27 Pechlivanoglou P. Economic evaluation of primary prevention of cardiovascular
28 diseases in mild hypertension: A scenario analysis for the Netherlands. *Clinical*
29 *Therapeutics*. 2014; 36(3):368-84.e5
- 30 143. Sundstrom J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J et al. Effects of
31 blood pressure reduction in mild hypertension: A systematic review and meta-
32 analysis. *Annals of Internal Medicine*. 2015; 162(3):184-91
- 33 144. Sundstrom J, Arima H, Woodward M, Jackson R, Karmali K, Lloyd-Jones D et al.
34 Blood pressure-lowering treatment based on cardiovascular risk: A meta-analysis of
35 individual patient data. *The Lancet*. 2014; 384(9943):591-598
- 36 145. Sundstrom J, Sheikhi R, Ostgren CJ, Svennblad B, Bodegard J, Nilsson PM et al.
37 Blood pressure levels and risk of cardiovascular events and mortality in type-2
38 diabetes: Cohort study of 34 009 primary care patients. *Journal of Hypertension*.
39 2013; 31(8):1603-10
- 40 146. Takase H, Tanaka T, Takayama S, Nonaka D, Machii M, Sugiura T et al. Recent
41 changes in blood pressure levels, hypertension prevalence and treatment rates, and
42 the rate of reaching target blood pressure in the elderly. *Medicine*. 2017;
43 96(50):e9116
- 44 147. The ADVANCE Collaborative Group. Rationale and design of the ADVANCE study: A
45 randomised trial of blood pressure lowering and intensive glucose control in high-risk
46 individuals with type 2 diabetes mellitus. *Action in Diabetes and Vascular Disease*:

- 1 PreterAx and DiamicroN Modified-Release Controlled Evaluation. *Journal of*
2 *Hypertension Supplement*. 2001; 19(4):S21-8
- 3 148. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on
4 outcome incidence in hypertension: 3. Effects in patients at different levels of
5 cardiovascular risk - Overview and meta-analyses of randomized trials. *Journal of*
6 *Hypertension*. 2014; 32(12):2305-2314
- 7 149. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on
8 outcome incidence in hypertension: 7. Effects of more vs. less intensive blood
9 pressure lowering and different achieved blood pressure levels - Updated overview
10 and meta-analyses of randomized trials. *Journal of Hypertension*. 2016; 34(4):613-
11 622
- 12 150. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment
13 on outcome incidence in hypertension: 10 - Should blood pressure management
14 differ in hypertensive patients with and without diabetes mellitus? Overview and
15 meta-analyses of randomized trials. *Journal of Hypertension*. 2017; 35(5):922-944
- 16 151. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment
17 on outcome incidence. 12. Effects in individuals with high-normal and normal blood
18 pressure: overview and meta-analyses of randomized trials. *Journal of Hypertension*.
19 2017; 35(11):2150-2160
- 20 152. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment
21 on cardiovascular outcomes and mortality: 13 - benefits and adverse events in older
22 and younger patients with hypertension: overview, meta-analyses and meta-
23 regression analyses of randomized trials. *Journal of Hypertension*. 2018; 36(8):1622-
24 1636
- 25 153. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA.
26 Antihypertensive treatment and secondary prevention of cardiovascular disease
27 events among persons without hypertension: A meta-analysis. *JAMA*. 2011;
28 305(9):913-922
- 29 154. Tiessen AH, Smit AJ, Broer J, Groenier KH, Meer K. Which patient and treatment
30 factors are related to successful cardiovascular risk score reduction in general
31 practice? Results from a randomized controlled trial. *BMC Family Practice*. 2013;
32 14:123
- 33 155. Tillin T, Orchard T, Malm A, Fuller J, Chaturvedi N. The role of antihypertensive
34 therapy in reducing vascular complications of type 2 diabetes. Findings from the
35 Diabetic REtinopathy Candesartan Trials-Protect 2 study. *Journal of Hypertension*.
36 2011; 29(7):1457-1462
- 37 156. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J et al. Effects of
38 different blood pressure-lowering regimens on major cardiovascular events in
39 individuals with and without diabetes mellitus: Results of prospectively designed
40 overviews of randomized trials. *Archives of Internal Medicine*. 2005; 165(12):1410-9
- 41 157. Ueshima H, Iimura O, Iida M, Okayama A, Sawai K, Minowa M. Impact of elevated
42 blood pressure on mortality from all causes, cardiovascular diseases, heart disease
43 and stroke among Japanese: 14 year follow-up of randomly selected population from
44 Japanese - Nippon data 80. *Journal of Human Hypertension*. 2003; 17(12):851-857
- 45 158. Veloudi P, Blizzard CL, Head GA, Abhayaratna WP, Stowasser M, Sharman JE.
46 Blood pressure variability and prediction of target organ damage in patients with
47 uncomplicated hypertension. *American Journal of Hypertension*. 2016; 29(9):1046-
48 1054

- 1 159. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A et al. Usual
2 versus tight control of systolic blood pressure in non-diabetic patients with
3 hypertension (Cardio-Sis): An open-label randomised trial. *The Lancet*. 2009;
4 374(9689):525-33
- 5 160. Vishram JK, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH et al. Blood
6 pressure variability predicts cardiovascular events independently of traditional
7 cardiovascular risk factors and target organ damage: A LIFE substudy. *Journal of*
8 *Hypertension*. 2015; 33(12):2422-2430
- 9 161. Wan EYF, Fong DYT, Fung CSC, Yu EYT, Chin WY, Chan AKC et al. Prediction of
10 five-year all-cause mortality in Chinese patients with type 2 diabetes mellitus - A
11 population-based retrospective cohort study. *Journal of Diabetes and Its*
12 *Complications*. 2017; 31(6):939-944
- 13 162. Wan EYF, Fung CSC, Yu EYT, Fong DYT, Chen JY, Lam CLK. Association of visit-
14 to-visit variability of systolic blood pressure with cardiovascular disease and mortality
15 in primary care Chinese patients with Type 2 diabetes: A retrospective population-
16 based cohort study. *Diabetes Care*. 2017; 40(2):270-279
- 17 163. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic
18 blood pressure lowering as determinants of cardiovascular outcome. *Hypertension*.
19 2005; 45(5):907-913
- 20 164. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on
21 interindividual variation in blood pressure and risk of stroke: A systematic review and
22 meta-analysis. *The Lancet*. 2010; 375(9718):906-915
- 23 165. Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D et al. Systolic blood
24 pressure and cardiovascular outcomes during treatment of hypertension. *American*
25 *Journal of Medicine*. 2013; 126(6):501-508
- 26 166. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB et al.
27 Cardiovascular events during differing hypertension therapies in patients with
28 diabetes. *Journal of the American College of Cardiology*. 2010; 56(1):77-85
- 29 167. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL et al. A comparison of
30 outcomes with angiotensin-converting-enzyme inhibitors and diuretics for
31 hypertension in the elderly. *New England Journal of Medicine*. 2003; 348(7):583-592
- 32 168. Wong MC, Tam WW, Wang HH, Cheung CS, Tong EL, Sek AC et al. Predictors of
33 the incidence of all-cause mortality and deaths due to diabetes and renal diseases
34 among patients newly prescribed antihypertensive agents: A cohort study.
35 *International Journal of Cardiology*. 2013; 168(5):4705-10
- 36 169. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T et al. Effects of intensive blood
37 pressure lowering on cardiovascular and renal outcomes: Updated systematic review
38 and meta-analysis. *The Lancet*. 2016; 387(10017):435-443
- 39 170. Yui Y, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S et al. Nifedipine retard was
40 an effective as angiotensin converting enzyme inhibitors in preventing cardiac events
41 in high-risk hypertensive patients with diabetes and coronary artery disease: The
42 Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup
43 analysis. *Hypertension Research*. 2004; 27(7):449-456
- 44 171. Yusuf S, Lonn E, Pais P, Bosch J, Lopez-Jaramillo P, Zhu J et al. Blood-pressure and
45 cholesterol lowering in persons without cardiovascular disease. *New England Journal*
46 *of Medicine*. 2016; 374(21):2032-43

- 1 172. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J et al. Effects of a polypill
2 (Polycap) on risk factors in middle-aged individuals without cardiovascular disease
3 (TIPS): A phase II, double-blind, randomised trial. *The Lancet*. 2009; 373(9672):1341-
4 1351
- 5 173. Yusuf S, Pais P, Sigamani A, Xavier D, Afzal R, Gao P et al. Comparison of risk
6 factor reduction and tolerability of a full-dose polypill (with potassium) versus low-
7 dose polypill (polycap) in individuals at high risk of cardiovascular diseases: The
8 Second Indian Polycap Study (TIPS-2) investigators. *Circulation Cardiovascular
9 quality and outcomes*. 2012; 5(4):463-471
- 10 174. Zamorano J, Erdine S, Pavia A, Kim JH, Al-Khadra A, Westergaard M et al. Proactive
11 multiple cardiovascular risk factor management compared with usual care in patients
12 with hypertension and additional risk factors: The CRUCIAL trial. *Current Medical
13 Research and Opinion*. 2011; 27(4):821-833
- 14 175. Zanchetti A, Hansson L, Clement D. Benefits and risks of more intensive blood
15 pressure lowering in hypertensive patients of the HOT study with different risk
16 profiles: Does a J-shaped curve exist in smokers? *Journal of Hypertension*. 2003;
17 21(4):787-804
- 18 176. Zheng L, Li J, Sun Z, Zhang X, Hu D, Sun Y. Relationship of blood pressure with
19 mortality and cardiovascular events among hypertensive patients aged ≥ 60 years in
20 rural areas of China: A strobe-compliant study. *Medicine*. 2015; 94(39):e1551
- 21

1 Appendices

2 Appendix A: Review protocols

3 Table 11: Review protocol: Initiating treatment

Field	Content
Review question	At what blood pressure and/or cardiovascular disease risk threshold should antihypertensive drug treatment be initiated for adults with hypertension?
Type of review question	Intervention review A review of health economic evidence related to the same review question was conducted in parallel with this review. For details, see the health economic review protocol for this NICE guideline.
Objective of the review	To establish which blood pressure or cardiovascular disease risk threshold antihypertensive drug treatment should be initiated at.
Eligibility criteria – population / disease / condition / issue / domain	Population: Adults (over 18 years) who are not on current pharmacological treatment for hypertension (minimum wash-out 4 weeks) Stratify by: <ul style="list-style-type: none"> • Presence or absence of type 2 diabetes • Cardiovascular or blood pressure baseline risk
Eligibility criteria – intervention(s) / exposure(s) / prognostic factor(s)	Treatment initiation at different thresholds <ul style="list-style-type: none"> • Systolic blood pressure targets: <ul style="list-style-type: none"> ○ Below 120 ○ 120–129 ○ 130–139 mmHg ○ 140–59 mmHg ○ 160 mmHg or above • Diastolic blood pressure targets: <ul style="list-style-type: none"> ○ <80 mmHg ○ 80–84 mmHg ○ 85–89 mmHg ○ 90–94 mmHg ○ 95 mmHg or above Cardiovascular risk thresholds: <ol style="list-style-type: none"> 1. 5–9% 2. 10–14% 3. 15–19% 4. Above 20% Data will be preferentially extracted if they compare across or within these categories; however, other comparisons will be considered in the absence of this.
Eligibility criteria – comparator(s) / control or reference (gold) standard	Compared against each other (comparing different blood pressure and/or cardiovascular risk thresholds) Also within each other
Outcomes and prioritisation	All outcomes to be measured at a minimum of 12 months. Where multiple time points are reported within each study, the longest time point only will be extracted.

	<p>Critical</p> <ul style="list-style-type: none"> • All-cause mortality • Health-related quality of life • Stroke (ischaemic or haemorrhagic) • Myocardial infarction <p>Important</p> <ul style="list-style-type: none"> • Heart failure needing hospitalisation • Vascular procedures (including lower limb, coronary and carotid artery procedures) • Angina needing hospitalisation • Side effect 1: Acute kidney injury • Side effect 2: New onset diabetes • Side effect 3: Treatment related admission • Side effect 4: Hypotension (dizziness) • [Combined cardiovascular disease outcomes in the absence of MI and stroke data] • [Coronary heart disease outcome in the absence of MI data]
Eligibility criteria – study design	<ol style="list-style-type: none"> 1. SRs (including IPD analyses) and RCTs that stratify or subgroup by baseline cardiovascular risk or blood pressure 2. Non-randomised studies that stratify by baseline cardiovascular risk or blood pressure <ul style="list-style-type: none"> • Confounders that should be adjusted for: <ul style="list-style-type: none"> ○ age ○ prior CV event ○ smoking ○ sex ○ BP (CV risk) <p>Note:</p> <ul style="list-style-type: none"> • Treatment must be received for a minimum of 1 year in study • Where an IPD meta-analysis is available that matches the protocol, this will be included and data published since will be presented separately. IPD meta-analysis is considered the highest quality evidence, therefore lower quality evidence will only be considered if it was published after the IPD.
Other inclusion exclusion criteria	<p>Exclusions:</p> <ul style="list-style-type: none"> • Non-comparative data where all participants start at the same treatment threshold (studies that do not stratify by 2 or more blood pressure or CV risk groups) • Studies including participants with type 1 diabetes or chronic kidney disease (A3 [heavy proteinuria]) or A2 or above for participants with type 2 diabetes. • Indirect populations with secondary causes of hypertension such as tumours or structural vascular defects (Conn's adenoma, pheochromocytoma, renovascular hypertension). • Pregnant women. • Children (under 18 years).
Proposed sensitivity / subgroup analysis, or meta-regression	No subgroups identified. The committee agreed that the stratification and adjustments required by this protocol encompassed the relevant confounding factors.
Selection process – duplicate screening / selection / analysis	Duplicate screening, selection and analysis will be undertaken on this review.

	A senior research fellow will undertake quality assurance prior to completion.
Data management (software)	Pairwise meta-analyses were performed using Cochrane Review Manager (RevMan5). GRADEpro was used to assess the quality of evidence for each outcome. Endnote for bibliography, citations, sifting and reference management.
Information sources – databases and dates	Medline, Embase, the Cochrane Library Date cut off: 2000 (restrict to papers published after this date) Language: Restrict to English only Key papers: Cochrane review (2017): http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010316.pub2/full
Identify if an update	Yes, 2011
Author contacts	https://www.nice.org.uk/guidance/cg127
Highlight if amendment to previous protocol	For details, please see section 4.5 of Developing NICE guidelines: the manual.
Search strategy – for 1 database	For details, please see appendix B
Data collection process – forms / duplicate	A standardised evidence table format will be used, and published as appendix D of the evidence report.
Data items – define all variables to be collected	For details, please see evidence tables in Appendix D (clinical evidence tables) or H (health economic evidence tables).
Methods for assessing bias at outcome / study level	Standard study checklists were used to appraise individual studies critically. For details, please see section 6.2 of Developing NICE guidelines: the manual The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group http://www.gradeworkinggroup.org/
Criteria for quantitative synthesis	For details, please see section 6.4 of Developing NICE guidelines: the manual.
Methods for quantitative analysis – combining studies and exploring (in)consistency	For details, please see the separate Methods report for this guideline.
Meta-bias assessment – publication bias, selective reporting bias	For details, please see section 6.2 of Developing NICE guidelines: the manual.
Confidence in cumulative evidence	For details, please see sections 6.4 and 9.1 of Developing NICE guidelines: the manual.
Rationale / context – what is known	For details, please see the introduction to the evidence review.
Describe contributions of authors and guarantor	A multidisciplinary committee developed the evidence review. The committee was convened by the National Guideline Centre (NGC) and chaired by Anthony Wierzbicki in line with section 3 of Developing NICE guidelines: the manual. Staff from NGC undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in

	collaboration with the committee. For details, please see Developing NICE guidelines: the manual.
Sources of funding / support	NGC is funded by NICE and hosted by the Royal College of Physicians.
Name of sponsor	NGC is funded by NICE and hosted by the Royal College of Physicians.
Roles of sponsor	NICE funds NGC to develop guidelines for those working in the NHS, public health and social care in England.
PROSPERO registration number	Not registered

1 Table 12: Health economic review protocol

Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below. No date cut-off from the previous guideline was used.
Review strategy	<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2002, abstract-only studies and studies from non-OECD countries or the US will also be excluded.</p> <p>Studies published after 2002 that were included in the previous guideline(s) will be reassessed for inclusion and may be included or selectively excluded based on their relevance to the questions covered in this update and whether more applicable evidence is also identified.</p> <p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).¹⁷</p> <p>Inclusion and exclusion criteria</p> <ul style="list-style-type: none"> • If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’, then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile. • If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’, then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile. • If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both, then there is discretion over whether it should be included. <p>Where there is discretion</p> <p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question in discussion with the guideline</p>

committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to exclude selectively the remaining studies. All studies excluded based on applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the US will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in 2002 or later (including any such studies included in the previous guideline[s]) but that depend on unit costs and resource data entirely or predominantly before 2002 will be rated as ‘Not applicable’.
- Studies published before 2002 (including any such studies included in the previous guideline[s]) will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review, the more useful the analysis will be for decision-making in the guideline.
- Generally, economic evaluations based on excludes from the clinical review will be excluded.

1 **Appendix B: Literature search strategies**

2 The literature searches for this review are detailed below and complied with the methodology
3 outlined in Developing NICE guidelines: the manual 2014, updated 2017

4 For more detailed information, please see the Methodology Review.

B.1.5 Clinical search literature search strategy

6 Searches were constructed using a PICO framework where population (P) terms were combined with
7 Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search
8 strategies for interventions as these concepts may not be well described in title, abstract or indexes
9 and therefore difficult to retrieve. Search filters were applied to the search where appropriate.

1 **Table 13: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline (OVID)	1946–02 October 2018	Exclusions Randomised controlled trials Systematic review studies Observational studies
Embase (OVID)	1974–02 October 2018	Exclusions Randomised controlled trials Systematic review studies Observational studies
The Cochrane Library (Wiley)	Cochrane Reviews to Issue 8 of 12, August 2018 CENTRAL to Issue 7 of 12, July 2018 DARE and NHS EED to Issue 2 of 4, April 2015 HTA to Issue 4 of 4, October 2016	None

2 **Table 14: Medline (Ovid) search terms**

1.	exp Hypertension/
2.	hypertens*.ti,ab.
3.	(elevat* adj2 blood adj pressur*).ti,ab.
4.	(high adj blood adj pressur*).ti,ab.
5.	(increase* adj2 blood pressur*).ti,ab.
6.	((systolic or diastolic or arterial) adj2 pressur*).ti,ab.
7.	or/1-6
8.	exp pregnancy/
9.	exp Hypertension, Pregnancy-Induced/ not exp Hypertension/
10.	(pre eclampsia or pre-eclampsia or preeclampsia).ti,ab.
11.	exp Hypertension, Portal/ not exp Hypertension/
12.	exp Hypertension, Pulmonary/ not exp Hypertension/
13.	exp Intracranial Hypertension/ not exp Hypertension/
14.	exp Ocular Hypertension/ not exp Hypertension/
15.	exp Diabetes Mellitus, Type 1/ not exp Diabetes Mellitus, Type 2/
16.	or/8-15
17.	7 not 16
18.	letter/
19.	editorial/
20.	news/
21.	exp historical article/
22.	Anecdotes as Topic/
23.	comment/
24.	case report/
25.	(letter or comment*).ti.
26.	or/18-25
27.	randomized controlled trial/ or random*.ti,ab.
28.	26 not 27
29.	animals/ not humans/

30.	exp Animals, Laboratory/
31.	exp Animal Experimentation/
32.	exp Models, Animal/
33.	exp Rodentia/
34.	(rat or rats or mouse or mice).ti.
35.	or/28-34
36.	17 not 35
37.	(exp child/ or exp pediatrics/ or exp infant/) not (exp adolescent/ or exp adult/ or exp middle age/ or exp aged/)
38.	36 not 37
39.	limit 38 to English language
40.	exp antihypertensive agents/
41.	(anti-hypertens* or antihypertens* or anti hypertens*).ti,ab.
42.	40 or 41
43.	risk factors/
44.	risk assessment/
45.	((initiat* or start* or commenc* or begin*) adj4 (treatment* or medicat*)).ti,ab.
46.	(risk* adj2 (factor* or assess*)).ti,ab.
47.	(threshold* or level*).ti,ab.
48.	or/43-47
49.	39 and 42 and 48
50.	randomized controlled trial.pt.
51.	controlled clinical trial.pt.
52.	randomi#ed.ti,ab.
53.	placebo.ab.
54.	randomly.ti,ab.
55.	Clinical Trials as topic.sh.
56.	trial.ti.
57.	or/50-56
58.	Meta-Analysis/
59.	exp Meta-Analysis as Topic/
60.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
61.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
62.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
63.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
64.	(search* adj4 literature).ab.
65.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
66.	cochrane.jw.
67.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
68.	or/58-67
69.	Epidemiologic studies/
70.	Observational study/
71.	exp Cohort studies/
72.	(cohort adj (study or studies or analys* or data)).ti,ab.

73.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
74.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
75.	Controlled Before-After Studies/
76.	Historically Controlled Study/
77.	Interrupted Time Series Analysis/
78.	(before adj2 after adj2 (study or studies or data)).ti,ab.
79.	or/69-78
80.	exp case control study/
81.	case control*.ti,ab.
82.	or/80-81
83.	79 or 82
84.	Cross-sectional studies/
85.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
86.	or/84-85
87.	79 or 86
88.	79 or 82 or 86
89.	49 and (57 or 68 or 88)

1 Table 15: Embase (Ovid) search terms

1.	exp Hypertension/
2.	hypertens*.ti,ab.
3.	(elevat* adj2 blood adj pressur*).ti,ab.
4.	(high adj blood adj pressur*).ti,ab.
5.	(increase* adj2 blood pressur*).ti,ab.
6.	((systolic or diastolic or arterial) adj2 pressur*).ti,ab.
7.	or/1-6
8.	exp pregnancy/
9.	exp Maternal Hypertension/
10.	(pre eclampsia or pre-eclampsia or preeclampsia).ti,ab.
11.	exp Hypertension, Portal/ not exp Hypertension/
12.	exp Hypertension, Pulmonary/ not exp Hypertension/
13.	exp Intracranial Hypertension/
14.	exp Ocular Hypertension/ not exp Hypertension/
15.	exp Diabetes Mellitus, Type 1/ not exp Diabetes Mellitus, Type 2/
16.	or/8-15
17.	7 not 16
18.	letter.pt. or letter/
19.	note.pt.
20.	editorial.pt.
21.	case report/ or case study/
22.	(letter or comment*).ti.
23.	or/18-22
24.	randomized controlled trial/ or random*.ti,ab.
25.	23 not 24
26.	animal/ not human/
27.	nonhuman/

28.	exp Animal Experiment/
29.	exp Experimental Animal/
30.	animal model/
31.	exp Rodent/
32.	(rat or rats or mouse or mice).ti.
33.	or/25-32
34.	17 not 33
35.	(exp child/ or exp pediatrics/) not (exp adult/ or exp adolescent/)
36.	34 not 35
37.	limit 36 to English language
38.	exp antihypertensive agent/
39.	(anti-hypertens* or antihypertens* or anti hypertens*).ti,ab.
40.	38 or 39
41.	risk factor/
42.	risk assessment/
43.	((initiat* or start* or commenc* or begin*) adj4 (treatment* or medicat*)).ti,ab.
44.	(risk* adj2 (factor* or assess*)).ti,ab.
45.	(threshold* or level*).ti,ab.
46.	or/41-45
47.	37 and 40 and 46
48.	random*.ti,ab.
49.	factorial*.ti,ab.
50.	(crossover* or cross over*).ti,ab.
51.	((doubl* or singl*) adj blind*).ti,ab.
52.	(assign* or allocat* or volunteer* or placebo*).ti,ab.
53.	crossover procedure/
54.	single blind procedure/
55.	randomized controlled trial/
56.	double blind procedure/
57.	or/48-56
58.	systematic review/
59.	meta-analysis/
60.	(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.
61.	((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
62.	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
63.	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
64.	(search* adj4 literature).ab.
65.	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
66.	cochrane.jw.
67.	((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
68.	or/58-67
69.	Clinical study/
70.	Observational study/
71.	family study/
72.	longitudinal study/

73.	retrospective study/
74.	prospective study/
75.	cohort analysis/
76.	follow-up/
77.	cohort*.ti,ab.
78.	76 and 77
79.	(cohort adj (study or studies or analys* or data)).ti,ab.
80.	((follow up or observational or uncontrolled or non randomi#ed or epidemiologic*) adj (study or studies or data)).ti,ab.
81.	((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort* or data)).ti,ab.
82.	(before adj2 after adj2 (study or studies or data)).ti,ab.
83.	or/69-75,78-82
84.	exp case control study/
85.	case control*.ti,ab.
86.	or/84-85
87.	83 or 86
88.	cross-sectional study/
89.	(cross sectional and (study or studies or review or analys* or cohort* or data)).ti,ab.
90.	or/88-89
91.	83 or 90
92.	83 or 86 or 90
93.	47 and (57 or 68 or 92)

1 **Table 16: Cochrane Library (Wiley) search terms**

#1.	MeSH descriptor: [Hypertension] explode all trees
#2.	hypertens*.ti,ab
#3.	(elevat* near/2 blood next pressur*):ti,ab
#4.	(high near/1 blood near/1 pressur*):ti,ab
#5.	(increase* near/2 blood pressur*):ti,ab
#6.	((systolic or diastolic or arterial) near/2 pressur*):ti,ab
#7.	(or #1-#6)
#8.	MeSH descriptor: [Antihypertensive Agents] explode all trees
#9.	(anti-hypertens* or antihypertens* or anti hypertens*):ti,ab
#10.	#8 or #9
#11.	MeSH descriptor: [Risk Factors] explode all trees
#12.	MeSH descriptor: [Risk Assessment] explode all trees
#13.	((initiat* or start* or commenc* or begin*) near/4 (treatment* or medicat*)):ti,ab
#14.	(risk* near/2 (factor* or assess*)):ti,ab
#15.	(threshold* or level*):ti,ab
#16.	#11 or #12 or #13 or #14 or #15
#17.	#7 and #10 and #16

B.2.2 Health Economics literature search strategy

- 3 Health economic evidence was identified by conducting a broad search relating to
- 4 hypertension in adults population in NHS Economic Evaluation Database (NHS EED – this
- 5 ceased to be updated after March 2015) and the Health Technology Assessment database

- 1 (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for
- 2 Research and Dissemination (CRD). Additional searches were run on Medline and Embase
- 3 for health economics, economic modelling and quality of life studies.

4 **Table 17: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline	2014–28 August 2018	Exclusions Health economics studies
Embase	2014–28 August 2018	Exclusions Health economics studies
Centre for Research and Dissemination (CRD)	HTA - Inception–28 August 2018 NHSEED - Inception to March 2015	None

5 **Table 18: Medline (Ovid) search terms**

1.	exp Hypertension/
2.	hypertens*.ti,ab.
3.	(elevat* adj2 blood adj pressur*).ti,ab.
4.	(high adj blood adj pressur*).ti,ab.
5.	(increase* adj2 blood pressur*).ti,ab.
6.	((systolic or diastolic or arterial) adj2 pressur*).ti,ab.
7.	or/1-6
8.	letter/
9.	editorial/
10.	news/
11.	exp historical article/
12.	Anecdotes as Topic/
13.	comment/
14.	case report/
15.	(letter or comment*).ti.
16.	or/8-15
17.	randomized controlled trial/ or random*.ti,ab.
18.	16 not 17
19.	animals/ not humans/
20.	exp Animals, Laboratory/
21.	exp Animal Experimentation/
22.	exp Models, Animal/
23.	exp Rodentia/
24.	(rat or rats or mouse or mice).ti.
25.	or/18-24
26.	7 not 25
27.	limit 26 to English language
28.	Economics/
29.	Value of life/
30.	exp "Costs and Cost Analysis"/
31.	exp Economics, Hospital/

32.	exp Economics, Medical/
33.	Economics, Nursing/
34.	Economics, Pharmaceutical/
35.	exp "Fees and Charges"/
36.	exp Budgets/
37.	budget*.ti,ab.
38.	cost*.ti.
39.	(economic* or pharmaco?economic*).ti.
40.	(price* or pricing*).ti,ab.
41.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
42.	(financ* or fee or fees).ti,ab.
43.	(value adj2 (money or monetary)).ti,ab.
44.	or/28-43
45.	27 and 44

1 Table 19: Embase (Ovid) search terms

1.	exp Hypertension/
2.	hypertens*.ti,ab.
3.	(elevat* adj2 blood adj pressur*).ti,ab.
4.	(high adj blood adj pressur*).ti,ab.
5.	(increase* adj2 blood pressur*).ti,ab.
6.	((systolic or diastolic or arterial) adj2 pressur*).ti,ab.
7.	or/1-6
8.	letter.pt. or letter/
9.	note.pt.
10.	editorial.pt.
11.	case report/ or case study/
12.	(letter or comment*).ti.
13.	or/8-12
14.	randomized controlled trial/ or random*.ti,ab.
15.	13 not 14
16.	animal/ not human/
17.	nonhuman/
18.	exp Animal Experiment/
19.	exp Experimental Animal/
20.	animal model/
21.	exp Rodent/
22.	(rat or rats or mouse or mice).ti.
23.	or/15-22
24.	7 not 23
25.	limit 24 to English language
26.	health economics/
27.	exp economic evaluation/
28.	exp health care cost/

29.	exp fee/
30.	budget/
31.	funding/
32.	budget*.ti,ab.
33.	cost*.ti.
34.	(economic* or pharmaco?economic*).ti.
35.	(price* or pricing*).ti,ab.
36.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
37.	(financ* or fee or fees).ti,ab.
38.	(value adj2 (money or monetary)).ti,ab.
39.	or/26-38
40.	25 and 39


1 Table 20: NHS EED and HTA (CRD) search terms

#1.	MeSH DESCRIPTOR Hypertension EXPLODE ALL TREES IN NHSEED,HTA
#2.	(Hypertens*) IN NHSEED, HTA
#3.	(elevat* adj2 blood adj pressur*) IN NHSEED, HTA
#4.	(high adj blood adj pressur*) IN NHSEED, HTA
#5.	(increase* adj2 blood pressur*) IN NHSEED, HTA
#6.	((systolic or diastolic or arterial) adj2 pressur*) IN NHSEED, HTA
#7.	#1 OR #2 OR #3 OR #4 OR #5 OR #6

2

1 Appendix C: Clinical evidence selection

Figure 2: Flow chart of clinical study selection for the review of initiating treatment in Hypertension



2

1 Appendix D: Clinical evidence tables

2

Study	Brunström 2018 ³⁶
Study type	Systematic Review
Number of studies (number of participants)	51 (n=192,795)
Countries and setting	Conducted in Multiple countries
Line of therapy	First line
Duration of study	Other: Each trial included had a minimum of 1,000 patient-years follow-up.
Method of assessment of guideline condition	Adequate method of assessment/diagnosis
Stratum	Mixed diabetic population
Subgroup analysis within study	Not applicable
Inclusion criteria	Randomized clinical trials with at least 1,000 patient-years of follow-up, comparing BP-lowering drugs versus placebo or different BP goals were included
Exclusion criteria	People with heart failure or left ventricular dysfunction and trials in the acute phase after myocardial infarction
Age, sex and family origin	Age - Other: Mean age 63.6 years. Sex (M/F): 60.1%/39.9%. Family origin: Multiple
Indirectness of population	Very serious indirectness: 23% of the population included with CAD, post-stroke, mixed CVD.
Interventions	<p>Intervention 1: Blood pressure threshold – 130–139 mmHg. People with blood pressure of <140 mmHg treated with antihypertensives. Duration over 1,000 person-years. Concurrent medication/care: Not stated. Indirectness: Serious indirectness; Indirectness comment: included trials with indirect population</p> <p>Intervention 2: Blood pressure threshold - 140–159 mmHg. People with blood pressure 140–159 mmHg treated with anti-hypertensives. Duration over 1,000 person-years. Concurrent medication or care: Not stated. Indirectness: Serious indirectness; Indirectness comment: Included trials with indirect population</p> <p>Intervention 3: Blood pressure threshold - greater than or equal to 160 mmHg. People with blood pressure greater or equal to 160 mmHg treated with antihypertensives. Duration over 1,000 person-years. Concurrent medication or care: Not stated. Indirectness: Serious indirectness; Indirectness comment: Included trials with indirect populations</p>

	<p>Intervention 4: Blood pressure threshold - 130–139 mmHg. People with blood pressure of <140 mmHg not treated with antihypertensives. Duration over 1,000 person-years. Concurrent medication or care: Not stated. Indirectness: Serious indirectness; Indirectness comment: Included trials with indirect populations</p> <p>Intervention 5: Blood pressure threshold - 140–159 mmHg. People with blood pressure 140–159 mmHg untreated. Duration over 1,000 person-years. Concurrent medication/care: Not stated. Indirectness: Serious indirectness; Indirectness comment: Included trials with indirect populations</p> <p>Intervention 6: Blood pressure threshold – greater than or equal to 160 mmHg. People with blood pressure equal to or greater than 160 mmHg untreated. Duration 1,000 person-years. Concurrent medication/care: Not stated. Indirectness: Serious indirectness; Indirectness comment: Included trials with indirect population Note: total number of participants in each intervention unclear</p>
Funding	Other (Of the 74 trials included, 70 reported funding. 56 were funded by industry and 14 by government grants or academia.)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: <140 mmHg TREATED versus <140 mmHg CONTROL

Protocol outcome 1: All-cause mortality

- Actual outcome for Mixed diabetic population: All-cause mortality at >1,000 person-years; Risk of bias: All domain - Very high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - High, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Serious indirectness

Protocol outcome 2: Stroke (ischaemic or haemorrhagic)

- Actual outcome for Mixed diabetic population: Stroke at >1,000 person-years; Risk of bias: All domain - Very high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - High, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Serious indirectness

Protocol outcome 3: Heart failure needing hospitalisation

- Actual outcome for Mixed diabetic population: Heart failure at >1,000 person-years; Risk of bias: All domain - Very high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - High, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Serious indirectness;

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: 140–159 mmHg TREATED versus 140–159 mmHg CONTROL

Protocol outcome 1: All-cause mortality

- Actual outcome for Mixed diabetic population: All-cause mortality at >1,000 person-years; Risk of bias: All domain - Very high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - High, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Serious indirectness

Protocol outcome 2: Stroke (ischaemic or haemorrhagic)

- Actual outcome for Mixed diabetic population: Stroke at >1,000 person-years; Risk of bias: All domain - Very high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - High, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Serious indirectness

Protocol outcome 3: Heart failure needing hospitalisation

- Actual outcome for Mixed diabetic population: Heart failure at >1,000 person-years; Risk of bias: All domain - Very high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - High, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Serious indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: GREATER THAN OR EQUAL TO 160 mmHg TREATED versus GREATER THAN OR EQUAL TO 160 mmHg CONTROL

Protocol outcome 1: All-cause mortality

- Actual outcome for Mixed diabetic population: All-cause mortality at >1,000 person-years;
Risk of bias: All domain - Very high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - High, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Serious indirectness

Protocol outcome 2: Stroke (ischaemic or haemorrhagic)

- Actual outcome for Mixed diabetic population: Stroke at >1,000 person-years; Risk of bias: All domain - Very high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - High, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Serious indirectness

Protocol outcome 3: Heart failure needing hospitalisation

- Actual outcome for Mixed diabetic population: Heart failure at >1,000 person-years; Risk of bias: All domain - Very high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - High, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Serious indirectness

Protocol outcomes not reported by the study

Health-related quality of life; Myocardial infarction; Vascular procedures (including lower limb, coronary and carotid artery procedures); Angina needing hospitalisation; Acute kidney injury; New onset diabetes; Treatment related admission; Hypotension (dizziness)

Study	Law 2009 ⁹⁰
Study type	Systematic Review
Number of studies (number of participants)	147 (n=464,000)
Countries and setting	Conducted in Multiple countries
Line of therapy	First line
Duration of study	Other: at least 1 year follow-up
Method of assessment of guideline condition	Systematic review: method of assessment mixed
Stratum	Mixed diabetic population
Subgroup analysis within study	Stratified then randomised
Inclusion criteria	Participants with no history of vascular disease, a history of coronary heart disease or a history of stroke
Exclusion criteria	Non-randomised trials and trials in which treated groups but not control groups had other interventions as well as blood pressure reduction, such as cholesterol reduction. Trials in people with chronic renal failure because these people typically have high blood pressure and high rates of cardiovascular disease and their response to standard blood pressure lowering therapy may differ from other people. Trials in which fewer than 5 coronary heart disease events and strokes were recorded or the duration of treatment was less than 6 months.
Age, sex and family origin	Age - Other: mean 64 years. Sex (M:F): Not stated. Family origin: Mixed
Extra comments	46,4000 adults with a total of 22,115 coronary heart disease events, 12,034 stroke events, 17,890 heart failure events, systolic blood pressure range of 112–194 mmHg, diastolic blood pressure range of 70–119.
Indirectness of population	Very serious indirectness: Indirect populations included with comorbidities such as CAD, stroke, heart failure
Interventions	<p>(n=21,807) Intervention 1: Diastolic blood pressure threshold - <80 mmHg. Treated people. Duration 4 years. Concurrent medication or care: Indirect population taking other drugs. Indirectness: Very serious indirectness</p> <p>(n=18,780) Intervention 2: Diastolic blood pressure threshold – 80–84 mmHg treated people. Duration 4 years. Concurrent medication or care: Indirect population taking other drugs. Indirectness: Very serious indirectness</p> <p>(n=23,105) Intervention 3: Diastolic blood pressure threshold – 85–89 mmHg treated people. Duration 4 years. Concurrent medication or care: Indirect population taking other drugs. Indirectness: Very serious indirectness</p> <p>(n=19,368) Intervention 4: Diastolic blood pressure threshold – 90–94 mmHg treated people. Duration 4</p>

	<p>years. Concurrent medication or care: Indirect population taking other drugs. Indirectness: Very serious indirectness</p> <p>(n=3,331) Intervention 5: Diastolic blood pressure threshold – greater than or equal to 95 mmHg treated people. Duration 4 years. Concurrent medication or care: Indirect population taking other drugs. Indirectness: Very serious indirectness</p> <p>(n=20,792) Intervention 6: Diastolic blood pressure threshold – <80 mmHg untreated people. Duration 4 years. Concurrent medication or care: taking other drugs. Indirectness: Very serious indirectness</p> <p>(n=18,736) Intervention 7: Diastolic blood pressure threshold – 80–84 mmHg untreated people. Duration 4 years. Concurrent medication or care: taking other drugs. Indirectness: Very serious indirectness</p> <p>(n=16,626) Intervention 8: Diastolic blood pressure threshold – 85–89 mmHg untreated people. Duration 4 years. Concurrent medication or care: taking other drugs. Indirectness: Very serious indirectness</p> <p>(n=19,278) Intervention 9: Diastolic blood pressure threshold - 90-94 mmHg untreated people. Duration 4 years. Concurrent medication or care: taking other drugs. Indirectness: Very serious indirectness</p> <p>(n=2,864) Intervention 10: Diastolic blood pressure threshold – greater than or equal to 95 mmHg untreated people. Duration 4 years. Concurrent medication or care: taking other drugs. Indirectness: Very serious indirectness</p>
Funding	Funding not stated (Systematic review)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: <80 mmHg TREATED versus <80 mmHg CONTROL</p>	
<p>Protocol outcome 1: Stroke (ischaemic or haemorrhagic) - Actual outcome for Mixed diabetic population: Stroke at 4 years; Group 1: 735/21,807, Group 2: 943/2,079 Risk of bias: All domain - Very high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Very serious indirectness</p>	
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: 80–84 mmHg TREATED versus 80–84 mmHg CONTROL</p>	
<p>Protocol outcome 1: Stroke (ischaemic or haemorrhagic) - Actual outcome for Mixed diabetic population: Stroke at 4 years; Group 1: 393/18,780, Group 2: 516/18,736 Risk of bias: All domain - Very high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Very serious indirectness</p>	

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: 85–89 mmHg TREATED versus 85–89 mmHg CONTROL

Protocol outcome 1: Stroke (ischaemic or haemorrhagic)

- Actual outcome for Mixed diabetic population: Stroke at 4 years; Group 1: 709/23,105, Group 2: 749/16,626

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Very serious indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: 90–94 mmHg TREATED versus 90–94 mmHg CONTROL

Protocol outcome 1: Stroke (ischaemic or haemorrhagic)

- Actual outcome for Mixed diabetic population: Stroke at 4 years; Group 1: 399/19,368, Group 2: 631/19,278

Risk of bias: All domain - Very high, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Very serious indirectness

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: GREATER THAN OR EQUAL TO 95 mmHg TREATED versus GREATER THAN OR EQUAL TO 95 mmHg CONTROL

Protocol outcome 1: Stroke (ischaemic or haemorrhagic)

- Actual outcome for Mixed diabetic population: Stroke at 4 years; Group 1: 123/3,331, Group 2: 209/2,864

Risk of bias: All domain - High, Selection - Low, Blinding - Low, Incomplete outcome data - High, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Very serious indirectness

Protocol outcomes not reported by the study	All-cause mortality; Health-related quality of life; Myocardial infarction; Heart failure needing hospitalisation; Vascular procedures (including lower limb, coronary and carotid artery procedures); Angina needing hospitalisation; Acute kidney injury; New onset diabetes; Treatment related admission; Hypotension (dizziness)
---	--

1

Study	Sheppard 2018 ¹³⁶
Study type	Non-randomised comparative study
Number of studies (number of participants)	(n=38,286)
Countries and setting	Conducted in the UK; Setting:
Line of therapy	1st line
Duration of study	Intervention and follow up: Median follow up (FU) – 5.8 years

Study	Sheppard 2018 ¹³⁶
Method of assessment of guideline condition	Adequate method of assessment or diagnosis
Stratum	Mixed diabetic population
Subgroup analysis within study	Not applicable
Inclusion criteria	Eligible people were those with mild hypertension (defined as 3 consecutive blood pressure readings between 140/90–159/99 mmHg within 12 months) and low cardiovascular disease risk. Low risk people were identified by excluding anyone with a history of cardiovascular disease, left ventricular hypertrophy, atrial fibrillation, diabetes, chronic kidney disease or family history of premature heart disease. Aged between 18–74 years. Linked general practice, Hospital Episodes Statistics (HES) and Office for National Statistics (ONS) mortality records and registered to an 'up to standard' clinical practice research datalink (CPRD) practice and classified as an 'acceptable patient'.
Exclusion criteria	Anyone with a history of cardiovascular disease, left ventricular hypertrophy, atrial fibrillation, diabetes, chronic kidney disease or family history of premature heart disease. Read code for previous cardiovascular disease (stroke, myocardial infarction, angina, coronary heart disease, peripheral vascular disease, heart failure), read code for cardiovascular risk factor (left ventricular hypertrophy, atrial fibrillation, diabetes or chronic kidney disease or family history of premature heart disease), record of any blood pressure lowering medication prescription in the 12 months prior to the third consecutive blood pressure reading between 140/90–159/99 mmHg, recorded or estimated cardiovascular risk score of >20% (sensitivity analysis only). QRISK2 cardiovascular risk levels was estimated by inserting age- and sex-standardised mean cholesterol values and Townsend scores from the Health Survey for England into the algorithm to replace missing data.
Recruitment/selection of patients	Individual patient data were extracted from the medical records of all people registered at general practices contributing to the CPRD in England with linked data to the Basic Inpatient HES and ONS mortality register.
Age, sex and family origin	Age - Mean (SD): 54.8 (12). Sex (M: F): Define. Family origin: 21,283 white, 757 black, 609 south Asian, 3307 mixed family origin, 504 other, 11,826 unknown
Further population details	Mean diastolic blood pressure of 88.5 mmHg in the control group, 88.7 mmHg in the treatment group
Indirectness of population	Very serious indirectness
Interventions	<p>(n=19,143) Intervention 1: Blood pressure threshold – 140–159 mmHg. People with blood pressure of 140–159 mmHg not treated with antihypertensives. Duration 5.8 years. Concurrent medication or care: N/A. Indirectness: No indirectness</p> <p>(n=19,143) Intervention 2: Blood pressure threshold – 140–159 mmHg. People with blood pressure of 140–159 mmHg treated with antihypertensives. Duration 5.8 years. Concurrent medication or care: N/A. Indirectness: No indirectness</p>

Study	Sheppard 2018 ¹³⁶
Funding	<p>Academic or government funding. This work was funded by Medical Research Council (MRC) Strategic Skills Postdoctoral Fellowship MR/K022032/1 (Dr Sheppard), a National Institute for Health Research (NIHR) professorship (Dr Sheppard and Mr McManus), and grant NIHR-RP-R2-12-015 from the NIHR (Mr McManus). Dr Sheppard receives funding from the NIHR Collaboration for Leadership in Applied Health Research and Care Oxford at Oxford Health National Health Service Foundation Trust and the NIHR School for Primary Care Research (SPCR). Mr Hobbs received support from the NIHR as director of the NIHR SPCR, director of the NIHR Collaboration for Leadership in Applied Health Research and Care Oxford, theme leader of the NIHR Oxford Biomedical Research Centre, and member of the NIHR Oxford Diagnostic Evidence Cooperative and from Harris Manchester College.)</p>
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: NO TREATMENT versus TREATMENT</p>	
<p>Protocol outcome 1: All-cause mortality at Longest reported - Actual outcome for Without type 2 diabetes: Mortality at 5.8 years; HR; 1.02 (95%CI 0.88 to 1.17); Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments -; Indirectness of outcome: No indirectness; Baseline details: N/A; Key confounders: Age, prior CV event, smoking, sex, BP (CV risk); Group 1 Number: 19,143; Group 2 Number: 19,143</p> <p>Protocol outcome 2: Stroke (ischaemic or haemorrhagic) at longest reported - Actual outcome for Without type 2 diabetes: Stroke at 5.8 years; HR; 0.97 (95%CI 0.78 to 1.21); Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments -; Indirectness of outcome: No indirectness; Baseline details: N/A; Key confounders: Age, prior CV event, smoking, sex, BP (CV risk); Group 1 Number: 19,143; Group 2 Number: 19,143</p> <p>Protocol outcome 3: Myocardial infarction at Longest reported - Actual outcome for Without type 2 diabetes: MI at 5.8 years; HR; 1.00 (95%CI 0.8 to 1.25); Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments -; Indirectness of outcome: No indirectness; Baseline details: N/A; Key confounders: Age, prior CV event, smoking, sex, BP (CV risk); Group 1 Number: 19,143; Group 2 Number: 19,143 - Actual outcome for Without type 2 diabetes: Non-MI acute coronary syndrome at 5.8 years; HR; 1.19 (95%CI 0.74 to 1.91); Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments -; Indirectness of outcome: No indirectness; Baseline details: N/A; Key confounders: Age, prior CV event, smoking, sex, BP (CV risk); Group 1 Number: 19,143; Group 2 Number: 19,143</p> <p>Protocol outcome 4: Heart failure needing hospitalisation at longest reported</p>	

Study	Sheppard 2018 ¹³⁶
	- Actual outcome for without type 2 diabetes: Heart failure at 5.8 years; HR; 1.34 (95%CI 0.96 to 1.86); Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments -; Indirectness of outcome: No indirectness; Baseline details: N/A; Key confounders: Age, prior CV event, smoking, sex, BP (CV risk); Group 1 Number: 19,143; Group 2 Number: 19,143
	Protocol outcome 5: Acute kidney injury at longest reported - Actual outcome for without type 2 diabetes: Acute kidney injury at 5.8 years; HR; 1.37 (95%CI 1 to 1.88); Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments -; Indirectness of outcome: No indirectness; Baseline details: N/A; Key confounders: Age, prior CV event, smoking, sex, BP (CV risk); Group 1 Number: 19,143; Group 2 Number: 19,143
	Protocol outcome 6: Hypotension (dizziness) at longest reported - Actual outcome for without type 2 diabetes: Hypotension at 5.8 years; HR; 1.69 (95%CI 1.3 to 2.2); Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Comments -; Indirectness of outcome: No indirectness; Baseline details: N/A; Key confounders: Age, prior CV event, smoking, sex, BP (CV risk); Group 1 Number: 19,143; Group 2 Number: 19,143
Protocol outcomes not reported by the study	Health-related quality of life at longest reported; Vascular procedures (including lower limb, coronary and carotid artery procedures) at longest reported; Angina needing hospitalisation at longest reported; New onset diabetes at longest reported; Treatment related admission at longest reported

1

Study	Sundstrom 2015 ¹⁴³
Study type	Systematic Review (IPD)
Number of studies (number of participants)	(n=6,361)
Countries and setting	Conducted in Multiple countries; Setting: Not specified
Line of therapy	First line
Duration of study	Intervention time: 4.4 years
Method of assessment of guideline condition	Adequate method of assessment or diagnosis
Stratum	With type 2 diabetes
Subgroup analysis within study	Not applicable
Inclusion criteria	RCTs of at least 1-year duration, people aged 18 years or older, at least 80% of whom had grade 1 hypertension and no previous cardiovascular disease, and compared an antihypertensive drug provided as

Study	Sundstrom 2015 ¹⁴³
	monotherapy or a stepped care algorithm against placebo or another control regimen. We examined the available sets of trials with individual-participant data included in the BPLTTC to identify subgroups of participants meeting the review inclusion criteria. These trials also met the original inclusion criteria for participation in the BPLTTC. Data from 4 sets of comparisons were included in these analyses: angiotensin-converting enzyme (ACE) inhibitors versus placebo, calcium-channel blockers versus placebo, diuretics versus placebo, and more intensive versus less intensive blood pressure lowering regimens.
Exclusion criteria	None specified
Recruitment/selection of patients	Not specified
Age, sex and family origin	Age - Mean (SD): 63.5 years (8.4). Sex (M:F): 2544:3817. Family origin: Not stated
Indirectness of population	No indirectness
Interventions	(n=3,364) Intervention 1: Blood pressure threshold – 140–159 mmHg. Trials comparing the following were included: ACE inhibitors versus placebo, calcium-channel blockers versus placebo, diuretics versus placebo, and more intensive versus less intensive blood pressure lowering regimens. Duration 4.4 years. Concurrent medication or care: Not specified. Indirectness: No indirectness (n=2,997) Intervention 2: Blood pressure threshold – 140–159 mmHg. Trials comparing the following were included: ACE inhibitors versus placebo, calcium-channel blockers versus placebo, diuretics versus placebo, and more intensive versus less intensive blood pressure lowering regimens. Duration 4.4 years. Concurrent medication or care: Not specified. Indirectness: No indirectness
Funding	Academic or government funding (funded by the Swedish Heart-Lung Foundation, Kjell och Marta Beijers Stiftelse, and the Swedish Research Council)
<p>RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: 140–159 mmHg (TREATED) versus 140–159 mmHg (NOT TREATED)</p> <p>Protocol outcome 1: All-cause mortality - Actual outcome for With type 2 diabetes: Total deaths at 4.4 years; Group 1: 230/3,355, Group 2: 268/2,979 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Very serious indirectness Risk of bias: All domain - Low, Crossover - Low; Indirectness of outcome: No indirectness</p> <p>Protocol outcome 2: Stroke (ischaemic or haemorrhagic) - Actual outcome for with type 2 diabetes: Stroke at 4.4 years; Group 1: 230/3,052, Group 2: 267/2,845 Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Very serious indirectness</p>	

Study	Sundstrom 2015 ¹⁴³
Risk of bias: All domain - Low, Crossover - Low; Indirectness of outcome: No indirectness	
Protocol outcome 4: Heart failure needing hospitalisation	
- Actual outcome for with type 2 diabetes: Heart failure at 4.4 years; Group 1: 62/2,872, Group 2: 76/2,757	
Risk of bias: All domain - Low, Selection - Low, Blinding - Low, Incomplete outcome data - Low, Outcome reporting - Low, Measurement - Low, Crossover - Low, Subgroups - Low, Other 1 - Very high; Indirectness of outcome: Very serious indirectness	
Risk of bias: All domain - Low, Crossover - Low; Indirectness of outcome: No indirectness	
Protocol outcomes not reported by the study	Health-related quality of life; Vascular procedures (including lower limb, coronary and carotid artery procedures); Angina needing hospitalisation; Acute kidney injury; New onset diabetes; Treatment related admission; Hypotension (dizziness)


1

1 Appendix E: Forest plots

E.1.2 Systolic blood pressure thresholds (mixed diabetic and non-diabetic population)


1.9.4.4 All-cause mortality at 4 years

Figure 3: Treatment versus no treatment in hypertensive and diabetic population




1.9.5.5 Stroke at 4 years

Figure 4: Treatment versus no treatment in hypertensive and diabetic population




1.9.6 1 Coronary heart disease at 4 years

Figure 5: Treatment versus no treatment in hypertensive and diabetic population



1.9.7 2 Heart failure at 4 years

Figure 6: Treatment versus no treatment in hypertensive and diabetic population



E.2.3 Systolic blood pressure thresholds (hypertensive and type 2 diabetes strata)

Figure 7: All-cause mortality at 4.4 years




Figure 8: Stroke at 4.4 years



1


Figure 9: Heart failure at 4.4 years



E.3.2 Diastolic blood pressure thresholds: treatment versus no treatment

1.9.8.4 Stroke

Figure 10: Treatment versus no treatment in hypertensive and diabetic population




Test for subgroup differences: Chi² = 14.52, df = 4 (P = 0.006), I² = 72.4%

1


E.4.2 Systolic blood pressure threshold of 140–159 mmHg: 3 treatment versus no treatment (no type 2 diabetes)

Figure 11: Mortality at 5.8 years




4

Figure 12: Stroke at 5.8 years




5

Figure 13: Myocardial Infarction at 5.8 years




6

Figure 14: Heart Failure at 5.8 years




7

Figure 15: Non-Myocardial Infarction Acute Coronary Syndrome at 5.8 years




8

Figure 16: Hypotension at 5.8 years



1

Figure 17: Acute Kidney Injury at 5.8 years



2

1 Appendix F: GRADE tables

2 Table 21: Clinical evidence profile: treatment versus no treatment at systolic blood pressure thresholds (with and without type 2
3 diabetes)

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment versus no treatment	Control	Relative (95% CI)	Absolute		
All-cause mortality - <140mmHg (follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	no serious imprecision	none	-	-	RR 0.98 (0.9 to 1.07)	[4,897 events in 68,16 people] ⁵	⊕⊕○○ LOW	CRITICAL
All-cause mortality - 140-159mmHg (follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	serious ¹	none	-	-	RR 0.87 (0.75 to 1.01)	7 fewer per 1000 (from 14 fewer to 1 more) ³	⊕○○○ VERY LOW	CRITICAL
All-cause mortality - ≥160mmHg (follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	no serious imprecision	none	-	-	RR 0.93 (0.87 to 0.99)	6 fewer per 1000 (from 1 fewer to 11 fewer) ³	⊕⊕○○ LOW	CRITICAL
Stroke - <140 (follow-up mean 4 years)												

1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	serious ¹	none	-	-	RR 0.85 (0.68 to 1.06)	4 fewer per 1000 (from 10 fewer to 2 more) ⁴	⊕⊕⊕⊕ VERY LOW	CRITICAL
Stroke - 140-159 (follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	serious ¹	none	-	-	RR 0.86 (0.72 to 1.03)	6 fewer per 1000 (from 12 fewer to 1 more) ⁴	⊕⊕⊕⊕ VERY LOW	CRITICAL
Stroke - ≥160 (follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	no serious imprecision ¹	none	-	-	RR 0.69 (0.6 to 0.79)	19 fewer per 1000 (from 13 fewer to 25 fewer) ⁴	⊕⊕⊕⊕ LOW	CRITICAL
Coronary heart disease - <140 mmHg (Copy; follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	Very serious ¹	no serious imprecision	none	-	-	RR 0.98 (0.88 to 1.09)	1 fewer per 1000 (from 8 fewer to 6 more) ⁴	⊕⊕⊕⊕ LOW	CRITICAL
Coronary heart disease - 140-159mmHg (Copy)												
1	no methodology chosen	no serious risk of bias	no serious inconsistency	Very serious ¹	serious ¹	none	-	-	RR 0.86 (0.76 to 0.97)	5 fewer per 1000 (from 1 fewer to 8 fewer) ⁴	⊕⊕⊕⊕ VERY LOW	CRITICAL
Coronary heart disease - ≥160mmHg (Copy)												
1	no methodology chosen	no serious risk of bias	no serious inconsistency	Very serious ¹	serious ¹	none	-	-	RR 0.86 (0.78 to 0.95)	8 fewer per 1000 (from 3 fewer to 12 fewer) ⁴	⊕⊕⊕⊕ VERY LOW	CRITICAL

Heart failure - <140mmHg (follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	serious ¹	none	-	-	RR 0.88 (0.78 to 0.99)	[2,261 events in 60,879 people] ⁵	⊕○○○ VERY LOW	IMPORTANT
Heart failure - 140-159mmHg (follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	serious ¹	none	-	-	RR 0.87 (0.73 to 1.04)	[1,113 events in 35,254 people] ⁵	⊕○○○ VERY LOW	IMPORTANT
Heart failure - ≥160mmHg (follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	no serious imprecision	none	-	-	RR 0.53 (0.42 to 0.67)	[520 events in 23,395 people] ⁵	⊕⊕○○ LOW	IMPORTANT

1 ¹ Downgraded by 1 increment due to population or outcome indirectness or by 2 increments for both population and outcome indirectness.

2 ² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

3 ³Control group risk not reported; values extrapolated from Bulpitt 198838

4 ⁴Control group risk not reported; values extrapolated from Law 200990

5 ⁵Control group risk not reported; therefore, absolute risk could not be calculated: no data was available that values could be extrapolated from. **Table 22: Clinical**

6 **evidence profile: Treatment versus no treatment at systolic blood pressure thresholds (type 2 diabetes)**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	No treatment (diabetes)	Relative (95% CI)	Absolute		

All-cause mortality - 140-159mmHg (follow-up mean 4.4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ¹	none	230/3355 (6.9%)	268/2979 (9%)	RR 0.76 (0.64 to 0.9)	22 fewer per 1000 (from 9 fewer to 32 fewer)	⊕⊕⊕○ MODERATE	CRITICAL
Stroke - 140-159mmHg (follow-up mean 4.4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ¹	none	230/3052 (7.5%)	267/2845 (9.4%)	RR 0.8 (0.68 to 0.95)	19 fewer per 1000 (from 5 fewer to 30 fewer)	⊕⊕⊕○ MODERATE	CRITICAL
Heart failure - 140-159mmHg (follow-up mean 4.4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ¹	none	62/2872 (2.2%)	76/2757 (2.8%)	RR 0.78 (0.56 to 1.09)	6 fewer per 1000 (from 12 fewer to 2 more)	⊕⊕⊕○ MODERATE	CRITICAL

1 ¹ Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

2 **Table 23: Clinical evidence profile: Treatment versus no treatment at diastolic blood pressure thresholds (with and without type 2 diabetes)**

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment versus no treatment	Control	Relative (95% CI)	Absolute		
Stroke (diastolic) - >80mmHg (follow-up mean 4 years)												

1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	serious ²	none	735/21807 (3.4%)	943/20792 (4.5%)	RR 0.74 (0.68 to 0.82)	12 fewer per 1000 (from 8 fewer to 15 fewer)	⊕○○○ VERY LOW	CRITICAL
Stroke (diastolic) - 80-84mmHg (follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	serious ²	none	393/18780 (2.1%)	516/18736 (2.8%)	RR 0.76 (0.67 to 0.87)	7 fewer per 1000 (from 4 fewer to 9 fewer)	⊕○○○ VERY LOW	CRITICAL
Stroke (diastolic) - 85-89mmHg (follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	no serious imprecision	none	709/23105 (3.1%)	749/16626 (4.5%)	RR 0.68 (0.62 to 0.75)	14 fewer per 1000 (from 11 fewer to 17 fewer)	⊕⊕○○ LOW	CRITICAL
Stroke (diastolic) - 90-94mmHg (follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	no serious imprecision	none	399/19368 (2.1%)	631/19278 (3.3%)	RR 0.63 (0.56 to 0.71)	12 fewer per 1000 (from 9 fewer to 14 fewer)	⊕⊕○○ LOW	CRITICAL
Stroke (diastolic) - >95mmHg (follow-up mean 4 years)												
1	randomised trials	no serious risk of bias	no serious inconsistency	very serious ¹	no serious imprecision	none	123/3331 (3.7%)	209/2864 (7.3%)	RR 0.51 (0.41 to 0.63)	36 fewer per 1000 (from 27 fewer to 43 fewer)	⊕⊕○○ LOW	CRITICAL

1 ¹ Downgraded by 1 increment due to population or outcome indirectness, or by 2 increments for both population and outcome indirectness.

2 ² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

1 **Table 24: Clinical evidence profile: Treatment versus no treatment at systolic blood pressure threshold of 140–159 mmHg (without**
2 **type 2 diabetes)**


Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Treatment	No treatment (no diabetes)	Relative (95% CI)	Absolute ³		
Mortality - 140-159mmHg (follow-up median 5.8 years)												
1	observational studies	no serious risk of bias	no serious inconsistency	very serious ¹	no serious imprecision	none	860/19143 (4.5%)	781/19143 (4.1%)	HR 1.02 (0.88 to 1.18) ⁴	1 more per 1000 (from 5 fewer to 7 more)	⊕○○○ VERY LOW	CRITICAL
Stroke - 140-159mmHg (follow-up median 5.8 years)												
1	observational studies	no serious risk of bias	no serious inconsistency	very serious ¹	serious ²	none	292/19143 (1.5%)	285/19143 (1.5%)	HR 0.97 (0.78 to 1.21) ⁴	0 fewer per 1000 (from 3 fewer to 3 more)	⊕○○○ VERY LOW	CRITICAL
Myocardial Infarction - 140-159mmHg (follow-up median 5.8 years)												
1	observational studies	no serious risk of bias	no serious inconsistency	very serious ¹	no serious imprecision	none	276/19143 (1.4%)	279/19143 (1.5%)	HR 1 (0.8 to 1.25) ⁴	0 fewer per 1000 (from 3 fewer to 4 more)	⊕○○○ VERY LOW	CRITICAL
Heart failure - 140-159mmHg (follow-up median 5.8 years)												
1	observational studies	no serious risk of bias	no serious inconsistency	very serious ¹	serious ²	none	169/19143 (0.88%)	131/19143 (0.68%)	HR 1.34 (0.96 to 1.87) ⁴	2 more per 1000 (from 0 fewer to 6 more)	⊕○○○ VERY LOW	IMPORTANT
Non-MI acute coronary syndrome - 140-159mmHg (follow-up median 5.8 years)												
1	observational studies	no serious risk of bias	no serious inconsistency	very serious ¹	very serious ²	none	61/19143 (0.32%)	56/19143 (0.29%)	HR 1.19 (0.74 to 1.91) ⁴	1 more per 1000 (from 1 fewer to 3 more)	⊕○○○ VERY LOW	IMPORTANT
Hypotension - 140-159mmHg (follow-up median 5.8 years)												

1	observational studies	no serious risk of bias	no serious inconsistency	very serious ¹	no serious imprecision	none	268/19143 (1.4%)	161/19143 (0.84%)	HR 1.69 (1.3 to 2.2) ⁴	6 more per 1000 (from 3 more to 10 more)	⊕○○○ VERY LOW	IMPORTANT
Acute Kidney Injury - 140-159mmHg (follow-up median 5.8 years)												
1	observational studies	no serious risk of bias	no serious inconsistency	very serious ¹	serious ²	none	194/19143 (1%)	144/19143 (0.75%)	HR 1.37 (1 to 1.88) ⁴	3 more per 1000 (from 0 more to 7 more)	⊕○○○ VERY LOW	IMPORTANT

- 1 ¹ Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively.
2 ² Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.
3 ³ Absolute effects calculated by inputting raw event data from median follow up time into GRADE.
4 ⁴ Evidence based on one study that reported HRs with raw event data.

1 Appendix G: Health economic evidence selection

Figure 18: Flow chart of health economic study selection for the guideline



* Non-relevant population, intervention, comparison, design or setting; non-English language

1 Appendix H: Health economic evidence tables

3 None.

4 Appendix I: Excluded studies

I.1.5 Excluded clinical studies

6 Table 25: Studies excluded from the clinical review

Study	Exclusion reason
Adamsson Eryd 2016 ¹	Incorrect study design, Incorrect population
Akanabe 1985 ²	Before 2000; incorrect analysis
ALLHAT collaborate research group 2000 ³	Incorrect comparison
Ambrosius 2014 ⁴	Incorrect comparison
Anand 2007 ⁶	Incorrect population (heart failure)
Anand 2008 ⁵	Incorrect population (heart failure)
Anavekar 2004 ⁷	No relevant outcomes
Anderson 2011 ⁸	Incorrect study design
Anon 2014 ⁹	Abstract
Arima 2006 ¹⁰	Study took place prior to 2000 date cut off
Arima 2009 ¹¹	Incorrect population (not treated)
Arnold 2003 ¹²	Incorrect analysis
Asayama 2009 ¹⁷	Incorrect population, study design and analysis
Asayama 2012 ¹⁵	No relevant outcomes
Asayama 2014 ¹⁹	Incorrect population
Asayama 2016 ¹⁴	No relevant outcomes
Asayama 2017 ¹³	No relevant outcomes, Incorrect comparison, incorrect population
Asayama 2018 ¹⁶	Already treated at baseline
Asayama 2014 ¹⁸	Incorrect population, study design and analysis
Aydogan 2015 ²¹	Already treated at baseline
Baker 2000 ²²	No relevant outcomes
Banach 2014 ²³	Incorrect study design
Barengo 2009 ²⁴	Incorrect comparison, incorrect analysis
Beckett 2014 ²⁵	Included in systematic review
Benavente 2013 ²⁶	Incorrect analysis (not adjusted)
Blacher 2000 ²⁷	Incorrect population
Black 2003 ²⁸	Incorrect comparison, no relevant outcomes
Blood Pressure Lowering Treatment Trialists 2008 ²⁹	Incorrect comparison
Bohm 2016 ³⁰	Incorrect population
Borghini 2004 ³¹	No relevant outcomes, data set before 2000
Boutitie 2002 ³²	No relevant outcomes
Brimble 2016 ³³	Not article

Study	Exclusion reason
Brown 2000 ³⁴	Incorrect population, Incorrect comparison
Bulpitt 2001 ³⁷	Incorrect population
Bundy 2017 ³⁹	Conference abstract
Bundy 2017 ⁴⁰	Incorrect comparison
Butler 2011 ⁴¹	Incorrect population
Carlsson 2013 ⁴²	Study took place prior to 2000 date cut off
Czernichow 2011 ⁴⁴	Incorrect population, incorrect comparison, incorrect study design
Deckers 2006 ⁴⁵	Incorrect population
Derosa 2014 ⁴⁶	Incorrect comparison
Derosa 2014 ⁴⁷	Article retracted
Dregan 2016 ⁴⁸	Incorrect analysis
Estacio 2006 ⁵⁰	Incorrect comparison
Ettehad 2016 ⁵¹	Systematic review; references checked
Fagard 1999 ⁵³	Study took place prior to 2000 date cut off
Fagard 2007 ⁵²	Incorrect population
Feldstein 2014 ⁵⁴	Incorrect population
Ferrucci 2001 ⁵⁶	Incorrect analysis
Filippi 2010 ⁵⁷	No relevant outcomes
Freitag 2003 ⁵⁸	Review, references checked
Frontoni 2014 ⁵⁹	Commentary
Fuchs 2011 ⁶⁰	Protocol
Fuchs 2016 ⁶¹	Included in systematic review
Garrison 2017 ⁶²	Incorrect comparison
Geraci 2003 ⁶³	Incorrect population
Grassi 2016 ⁶⁴	Literature review
Gueyffier 1997 ⁶⁶	No relevant outcomes
Gueyffier 1999 ⁶⁵	Study took place prior to 2000 date cut off
Hansen 2007 ⁶⁷	Study took place prior to 2000 date cut off
Hara 2014 ⁶⁸	Incorrect population
Ho 2018 ⁶⁹	Incorrect comparison
Hong 2018 ⁷⁰	Systematic review, references checked
Howard 2008 ⁷¹	Incorrect comparison
Huse 2000 ⁷²	Incorrect study design
In der Schmitt 2013 ⁷³	Incorrect study design
Isezuo 2003 ⁷⁴	Incorrect population
Ishikawa 2008 ⁷⁵	Incorrect analysis
Izzo 2011 ⁷⁶	Review; references checked
Jacobs 2017 ⁷⁷	Incorrect comparison
JATOS study group 2008 ⁷⁸	Incorrect interventions
Johnson 1993 ⁷⁹	incorrect population
Julius 2006 ⁸⁰	No useable outcomes
Kagiyama 2008 ⁸¹	Study took place prior to 2000 date cut off
Kalkman 2017 ⁸²	Meta-analysis; references checked
Karmali 2017 ⁸³	Incorrect comparison
Kengne 2009 ⁸⁴	No useable outcomes

Study	Exclusion reason
Kim 2013 ⁸⁵	No relevant outcomes
Kokubo 2008 ⁸⁶	Incorrect comparison
Ku 2018 ⁸⁷	Incorrect population
Lachouri 2009 ⁸⁹	No relevant outcomes
Le 2017 ⁹¹	No relevant outcomes
Lee 2012 ⁹²	No relevant outcomes
Li 2005 ⁹³	Incorrect population
Li 2014 ⁹⁵	Abstract
Li 2016 ⁹⁴	Adjusted for treatment
Lithell 2003 ⁹⁶	Incorrect study design
Liu 2009 ⁹⁸	Included studies before cut off 2000
Liu 2015 ⁹⁷	Incorrect population
Lonn 2016 ⁹⁹	Incorrect population, no relevant outcomes, incorrect interventions
Lonn 2016 ¹⁰⁰	Incorrect population, no relevant outcomes, incorrect interventions
Lopez-Paz 2010 ¹⁰¹	Abstract
Luders 1002 ¹⁰²	No relevant outcomes
Lund Haheim 1995 ¹⁰³	Study took place prior to 2000 date cut off
Ma 2012 ¹⁰⁴	Inappropriate washout period
MacMahon 2001 ¹⁰⁵	Incorrect population
Mancia 2016 ¹⁰⁶	Incorrect comparison
Margolis 2014 ¹⁰⁷	Incorrect population
Mariampillai 2016 ¹⁰⁸	Commentary
Mehlum 2018 ¹⁰⁹	No useable data
Meredith 2008 ¹¹¹	Incorrect population
Meredith 2016 ¹¹⁰	Incorrect comparison
Moraes 2017 ¹¹²	Systematic review, references checked
Muntner 2017 ¹¹³	No relevant outcomes
Myers 2016 ¹¹⁴	Incorrect comparison
Nakamura 2006 ¹¹⁵	Study took place prior to 2000 date cut off
Nelson 2015 ¹¹⁸	Incorrect analysis
Ninomiya 2008 ¹¹⁹	Incorrect population
Nissen 2004 ¹²⁰	Incorrect comparison
Ntaios 2011 ¹²¹	No useable data
Obara 2007 ¹²²	Incorrect comparison
Ogihara 2008 ¹²³	Incorrect comparison
Ogihara 2010 ¹²⁴	Incorrect population (already treated)
Ohkuma 2017 ¹²⁵	No relevant outcomes
Papademetriou 2016 ¹²⁶	Incorrect comparison
Patel 2007 ¹²⁷	Incorrect comparison
Patel 2017 ¹²⁸	No relevant outcomes
Pocock 2001 ¹²⁹	Study took place prior to 2000 date cut off
Pringle 2003 ¹³⁰	Incorrect interventions
Redon 2012 ¹³¹	Incorrect study design
Remme 2009 ¹³²	Incorrect analysis

Study	Exclusion reason
Rouleau 2004 ¹³³	No relevant outcomes
Ruggenti 2012 ¹³⁴	Incorrect study design
Shapiro 2018 ¹³⁵	Incorrect comparison
Shiraishi 2012 ¹³⁸	Incorrect population
Singh 2012 ¹³⁹	Conference abstract
Sipahi 2012 ¹⁴⁰	Systematic review, references checked
Sleight 2009 ¹⁴¹	Order cancelled
Sundstrom 2013 ¹⁴⁵	Incorrect population
Sundstrom 2014 ¹⁴⁴	Incorrect study design
Takase 2017 ¹⁴⁶	Incorrect study design
The ADVANCE Collaborative Group 2001 ¹⁴⁷	Incorrect interventions; incorrect analysis
Thomopoulos 2014 ¹⁴⁸	Systematic review, references checked
Thomopoulos 2014 ¹⁵⁰	Systematic review, references checked
Thomopoulos 2016 ¹⁴⁹	Incorrect comparison
Thomopoulos 2017 ¹⁵¹	Incorrect comparison
Thomopoulos 2018 ¹⁵²	Systematic review, references checked
Thompson 2011 ¹⁵³	Incorrect analysis
Tiessen 2013 ¹⁵⁴	Incorrect interventions
Tillin 2011 ¹⁵⁵	Incorrect population
Turnbull 2005 ¹⁵⁶	Systematic review, references checked
Ueshima 2003 ¹⁵⁷	Study took place prior to 2000 date cut off
Veloudi 2016 ¹⁵⁸	No relevant outcomes
Verdecchia 2009 ¹⁵⁹	Incorrect population (already treated)
Vishram 2015 ¹⁶⁰	No relevant outcomes
Wan 2017 ¹⁶²	No relevant outcomes
Wan 2017 ¹⁶¹	incorrect study design, incorrect study population
Wang 2005 ¹⁶³	Incorrect comparison
Webb 2010 ¹⁶⁴	No relevant outcomes
Weber 2010 ¹⁶⁶	No relevant outcomes
Weber 2013 ¹⁶⁵	Incorrect comparison
Wing 2003 ¹⁶⁷	Before cut off of 2000; previously treated
Wong 2013 ¹⁶⁸	No relevant outcomes
Xie 2016 ¹⁶⁹	Incorrect population; incorrect analysis
Yui 2004 ¹⁷⁰	Incorrect comparison
Yusuf 2009 ¹⁷²	Incorrect comparison
Yusuf 2012 ¹⁷³	Less than minimum duration; Incorrect comparison
Yusuf 2016 ¹⁷¹	Incorrect population, no relevant outcomes, incorrect interventions
Zamorano 2011 ¹⁷⁴	No relevant outcomes
Zanchetti 2003 ¹⁷⁵	Incorrect comparison
Zheng 2015 ¹⁷⁶	Incorrect comparison

I.2.1 Excluded health economic studies

2 **Table 26: Studies excluded from the health economic review**

Reference	Reason for exclusion
Athanasakis 2011 ²⁰	This study was assessed as partially applicable with very serious limitations because although it is comparing treatment versus no treatment in a hypertensive population, the treatment effect is based on observational systolic BPs in a treated and untreated group being put into a risk calculator as above.
Ferret 2017 ⁵⁵	This study was assessed as not applicable because the intervention that is being compared in different CV risk subgroups is a polypill that also includes a statin.
Kyridemos 2018 ⁸⁸	This study was assessed as not applicable because it is comparing different types of implementation of NHS health check, which can lead to identification of many conditions and not just hypertension, so it is not just about antihypertensive treatment.
Stevanovic 2014 ¹⁴²	This study was assessed as partially applicable with very serious limitations because although it is comparing treatment versus no treatment in a hypertensive population, it uses a different risk calculator to what would be used in the UK. It also uses BP reduction for treatment effect (rather than a relative risk reduction in events) and predicts events through the calculator which should ideally be used only for baseline risks. It also has different treatment steps to UK practice.

3

1 Appendix J: Research recommendations

J.1.2 Threshold interventions

3 **Research question: In adults aged under 40 with hypertension (with or without type 2**
 4 **diabetes), what are the appropriate risk and blood pressure thresholds for starting**
 5 **treatment?**

6 **Why this is important:**

7 There is uncertainty about how to assess the impact of blood pressure treatment in people
 8 aged under 40 with stage 1 hypertension and no overt target organ damage or
 9 cardiovascular disease. Although it is inevitable that those with untreated hypertension will
 10 develop premature target organ damage over the many years and decades they are
 11 affected, it is unclear at what level of 10-year or lifetime vascular risk pharmacological
 12 treatment of hypertension in those aged under 40 will be cost effective. The economic model
 13 in this guideline suggests that treating stage 1 hypertension is cost effective at lower levels of
 14 10-year risk in younger people than in older people. The 10-year Q-RISK2 risk at which
 15 treatment of 40 year olds with stage 1 hypertension without target organ damage is cost
 16 effective at the minimal willingness to pay threshold of £20K per QALY using probabilistic
 17 ICERs, is as low as 0.83% (males) and 1.86% (females). This implies that all 40-year-old
 18 males with uncomplicated stage 1 hypertension should be offered treatment since their
 19 cardiovascular risk is typically greater than this threshold.

20 Cost effectiveness of treating those aged under 40 is a key issue for regional specialist
 21 hypertension services, the many affected people and the wider NHS. It is recognised that
 22 longer than usual follow up will be required to answer this question with hard outcomes
 23 including all-cause mortality, heart attack and stroke.

24 **Criteria for selecting high-priority research recommendations:**

PICO question	Population: People with hypertension aged under 40 with or without target organ damage (stratified by BP or cardiovascular risk). Intervention(s): Lifestyle and pharmacological interventions to lower blood pressure. Comparison: Lifestyle intervention with no antihypertensive treatment. Outcome(s): All-cause mortality, myocardial infarction, stroke and health related quality of life.
Importance to patients or the population	An increasing number of people are recognised to have hypertension whose onset occurs at aged under 40. The lifetime cardiovascular risk to people and health cost to the NHS of this phenomenon is currently poorly characterised.
Relevance to NICE guidance	High quality research in this area may enable future updates of this guidance to make a strong recommendation on the cost utility thresholds at which treatment of people aged under 40 is beneficial.
Relevance to the NHS	People with a young onset of hypertension have often more than 50 years of life during which treatment may be effective, and the NHS has more than half a century of health costs to meet per affected individual. It seems likely that cheap effective treatment early on may reduce lifetime healthcare cost to the NHS from vascular events.
National priorities	Balancing the health needs of the young is important since most treatments in cardiovascular disease are focused on the elderly.
Current evidence base	Hypertension in adults 2019 NICE guideline update of CG127: no evidence specific to people aged under 40 was identified in the evidence review included in this guideline.
Equality	None.

Study design	A long-term follow up of an RCT with people randomised to treatment (randomisation to 'A' versus 'C' drugs) plus lifestyle advice versus lifestyle advice only.
Feasibility	Realisation from funders that such an important issue requires longer than usual follow up for vascular outcomes and all-cause mortality. Multiple funders may be required to share the risks of a long-term study.
Other comments	None
Importance	High: the research is essential to inform future updates of key recommendations in the guideline. This issue will affect the UK population indefinitely and so answering it as soon as possible, even if that takes a decades-long study, is a good use of limited resources.

1